

NOVEL MOLECULES OF THE MULTI-DRUG AND TOXIN EFFLUX (MATE) PROTEIN FAMILY AND USES THEREOF

Related Applications

5 The present application is a continuation of PCT patent application
number PCT/US02/09962, filed on March 27, 2002, which claims priority to U.S.
provisional application serial no. 60/280,621, filed on March 30, 2001 and entitled
Novel Molecules of the Multi-Drug and Toxin Efflux (MATE) Protein Family and Uses
Thereof, the entire contents of which is expressly incorporated herein by reference.

10

Government Interests

Work described herein was supported in part by funding from the Life
Sciences Research Foundation (LSRF) and the National Science Foundation (NSF),
Contract No. IBN-9974837. The United States Government has certain rights in the
invention.

15

Background of the Invention

Iron deficiency is one of the most common human nutritional disorders in
the world today (<http://www.who.int/nut/ida.htm>; Yip, R. (1994) *J. Nutr.* 124: 1479S-
20 1490S). Indeed, iron is an essential nutrient for virtually all organisms because it plays a
critical role in important biochemical processes such as respiration and photosynthesis.
Although abundant in nature, iron is often available in limited amounts because the
oxidized form, Fe(III), is extremely insoluble at neutral or basic pH. This fact is of
particular importance to agriculture because approximately one-third of the world's soils
25 are classified as iron-deficient (Yi, Y. *et al.* (1994) *Plant Physiol.* 104: 815-820). Many
"iron-efficient" plant varieties have iron uptake strategies (designated strategy I or
strategy II) that are directed at solubilizing iron (Römheld, V. (1987) *Physiol. Plant.* 70:
231-234). Strategy II plants, which include all of the grasses, release Fe(III) compounds
called "phytosiderophores" into the surrounding soil that bind iron and are then taken up
30 into the roots. Most other iron-efficient plants use strategy I and respond to iron
deprivation by inducing the activity of membrane-bound Fe(III) chelate reductases that
reduce Fe(III) to the more soluble Fe(II) form. The Fe(II) product is then taken up into
the roots by an Fe(II) specific transport system that is also induced by iron-limiting
growth conditions. Furthermore, the roots of strategy I plants release more protons when
35 iron-deficient, lowering the rhizosphere pH and thereby increasing the solubility of

Fe(III). Thus, it would be desirable to take advantage of this understanding of iron-uptake strategies to produce plants which have increased iron-uptake capabilities.

In addition, metal ion pollution is perhaps one of the most difficult environmental problems facing the industrial world today. Unlike the organic and even halogenated organic pollutants, which can be degraded in the soil, metals are essentially nonmutable. The electrolytic, *in situ* immobilization and chemical leaching technologies for cleaning polluted sites are all very expensive, particularly in light of how vast some of these sites are. With the exception of approaches like vitrification, most *in situ* metal ion remediation schemes require some mechanism for increased mobilization of the metal ion. This raises the possibility of further endangering local wildlife or adjacent ecosystems not already affected. Thus, a need still exists for better methods for removing toxic pollutants from the soil.

Summary of the Invention

This invention is based, at least in part, on the discovery of the functional characteristics of the wild type ferric reductase defective (FRD3) nucleic acid and protein molecules and the discovery of novel mutant FRD3 molecules. Designated herein as "FRD3 nucleic acid and protein molecules," this novel group of molecules belongs to the multi-drug and toxin efflux (MATE) family, and includes, for example, FRD3 molecules such as FRD3, FRD3-1, FRD3-2, and FRD3-3 (FRD3-3 is also referred to herein as MAN1) molecules.

Wild type FRD3 nucleic acid and protein molecules, such as FRD3, are expressed in plants under metal deficient conditions, *e.g.*, iron deficient conditions, and are capable of increasing metal uptake in plants under such conditions and decreasing metal uptake in plants under metal sufficient conditions. In contrast, mutant FRD3 nucleic acid and protein molecules, such as FRD3-1, FRD3-2, and FRD3-3, are expressed under both metal sufficient and metal deficient conditions which results in an increase of metal uptake in plants under both metal sufficient and deficient conditions. Accordingly, wild type FRD3 and mutant FRD3 nucleic acid and protein molecules are useful as modulating agents in regulating metal homeostasis, *e.g.*, iron homeostasis.

The FRD3 nucleic acid and protein molecules share several structural/functional properties. Structurally, FRD3 polypeptides are expressed in the roots but not in shoots of plants and include, for example, at least one transmembrane domain belonging to the MATE family of molecules (Brown *et al.*, Mol. Micro., 31:393, 1999), preferably approximately ten to twelve transmembrane domains. Functionally, FRD3 nucleic acid and protein molecules are capable of, for example, expressing metal

deficiency responses, *e.g.*, iron deficiency responses. In particular, wild type FRD3 molecules are capable of increasing metal uptake in plants under metal deficient conditions and decreasing metal uptake in plants under metal sufficient conditions. Mutant FRD3 molecules, *e.g.*, FRD3-1, FRD3-2, and FRD3-3, are capable of expressing metal deficiency responses under both metal deficient and metal sufficient conditions. Mutant FRD3 molecules are also capable of, (1) misexpressing ferric chelate reductase activity, (2) overaccumulating metals, *e.g.*, iron, or (3) causing chlorosis. In particular, while not intending to be limited to any theory, it is believed that the FRD3 nucleic acid and protein molecules serve as a receptor for metal deficiency signals, for example, a receptor for iron deficiency signals. Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding FRD3 proteins or biologically active portions thereof, as well as nucleic acid fragments suitable as primers or hybridization probes for the detection of *frd3*-encoding nucleic acids.

In one embodiment, a *frd3* nucleic acid molecule of the invention is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 89%, 90%, 95%, 96%, 97%, 98%, 99% or more identical to the nucleotide sequence (*e.g.*, to the entire length of the nucleotide sequence) shown in SEQ ID NO:1, 2, 4, 5, 7, 8, 20, or a complement thereof.

In a preferred embodiment, the isolated nucleic acid molecule includes the nucleotide sequence shown in SEQ ID NO:1, 2, 4, 5, 7, 8, 20, or a complement thereof. In another embodiment, the nucleic acid molecule includes the coding region of SEQ ID NO:2 (nucleotides 118-1698), the coding region of SEQ ID NO:5 (nucleotides 118-1182), the coding region of SEQ ID NO:8 (nucleotides 118-870), or the coding region of SEQ ID NO:20 (nucleotides 118-1698). In yet a further embodiment, the nucleic acid molecule includes the coding region of SEQ ID NO:2 and nucleotides 1-117 or 1699-1868 of SEQ ID NO:1, the coding region of SEQ ID NO:5 and nucleotides 1-117 or 1183-1867 of SEQ ID NO:5, the coding region of SEQ ID NO:8 and nucleotides 1-117 or 871-1950 of SEQ ID NO:1, or the coding region of SEQ ID NO:20 and nucleotides 1-117 or 1699-1950 of SEQ ID NO:20. In another preferred embodiment, the nucleic acid molecule consists of the nucleotide sequence shown in SEQ ID NO: 1, 2, 4, 5, 7, 8, 20, or the coding region thereof.

In another embodiment, a *frd3* nucleic acid molecule includes a nucleotide sequence encoding a protein having an amino acid sequence sufficiently identical to the amino acid sequence of SEQ ID NO:3, 6, 9, or 10. In a preferred embodiment, a *frd3* nucleic acid molecule includes a nucleotide sequence encoding a protein having an amino acid sequence at least 50%, 55%, 60%, 65%, 70%, 75%, 80%,

85%, 89%, 90%, 95%, 96%, 97%, 98%, 99% or more identical to the entire length of the amino acid sequence of SEQ ID NO: 3, 6, 9, or 10.

In another preferred embodiment, an isolated nucleic acid molecule encodes the amino acid sequence of a FRD3 polypeptide (*e.g.*, an *A. thaliana* FRD3-1 polypeptide, an *A. thaliana* FRD3-2 polypeptide, or an *A. thaliana* FRD3-3 polypeptide). In yet another preferred embodiment, the nucleic acid molecule includes a nucleotide sequence encoding a protein having the amino acid sequence of SEQ ID NO:3, 6, 9, or 10. In yet another preferred embodiment, the nucleic acid molecule is at least 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 653, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700 or more nucleotides in length. In a further preferred embodiment, the nucleic acid molecule is at least 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 653, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700 or more nucleotides in length and encodes a protein having a FRD3 activity (as described herein).

Another embodiment of the invention features nucleic acid molecules, preferably *frd3* nucleic acid molecules, which specifically detect *frd3* nucleic acid molecules relative to nucleic acid molecules encoding non-FRD3 proteins. For example, in one embodiment, such a nucleic acid molecule is at least 20, 30, 40, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 653, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700 or more nucleotides in length and hybridizes under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence shown in SEQ ID NO:1, 2, 4, 5, 7, 8, 20, or a complement thereof.

In preferred embodiments, the nucleic acid molecules are at least 15 nucleotides (*e.g.*, 15 contiguous nucleotides) in length and hybridize under stringent conditions to the nucleotide molecules set forth in SEQ ID NO: 1, 2, 4, 5, 7, 8, 20, or a complement thereof. In certain embodiments, the nucleic acid molecules are at least 15 nucleotides in length and hybridize under stringent conditions to nucleotides 1-117 and 1699-1868 of SEQ ID NO:2, nucleotides 1-117 and 1183-1867 of SEQ ID NO:5, nucleotides 1-117 and 871-1950 of SEQ ID NO:8, or nucleotides 1-117 and 1699-1868 of SEQ ID NO:20. In another embodiment, the nucleic acid molecules comprise nucleotides 1-117 and 1699-1868 of SEQ ID NO:2, nucleotides 1-117 and 1183-1867 of SEQ ID NO:5, nucleotides 1-117 and 871-1950 of SEQ ID NO:8, or nucleotides 1-117 and 1699-1868 of SEQ ID NO:20.

In other preferred embodiments, the nucleic acid molecule encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence

of SEQ ID NO:3, 6, 9, or 10, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO:1, 2, 4, 5, 7, 8, 20, or a complement thereof, under stringent conditions.

5 Another embodiment of the invention provides an isolated nucleic acid molecule which is antisense to a *frd3* nucleic acid molecule, *e.g.*, the coding strand of a *frd3* nucleic acid molecule. Double stranded RNA comprising *frd3*-specific sequences in the sense and antisense orientations and capable of duplex formation with *frd3* genes is also within the scope of the present invention.

10 Another aspect of the invention provides a vector comprising a *frd3* nucleic acid molecule. In certain embodiments, the vector is a recombinant expression vector. In another embodiment, the invention provides a host cell containing a vector of the invention. In yet another embodiment, the invention provides a host cell containing a nucleic acid molecule of the invention. The invention also provides a method for producing a protein, preferably a FRD3 protein, by culturing in a suitable medium, a
15 host cell, *e.g.*, a mammalian host cell such as a non-human mammalian cell, of the invention containing a recombinant expression vector, such that the protein is produced.

Another aspect of this invention features isolated, *e.g.*, isolated from the *Arabidopsis* family of plants, recombinant, or synthetic FRD3 proteins and polypeptides (*e.g.*, FRD3-1, FRD3-2, and FRD3-3). In one embodiment, an isolated FRD3 protein
20 includes at least one transmembrane domain belonging to the MATE family of molecules, preferably approximately ten to twelve transmembrane domains.

In a preferred embodiment, a FRD3 protein includes at least one transmembrane domain belonging to the MATE family of molecules and has an amino acid sequence at least about 50%, 55%, 60%, 65%, 67%, 68%, 70%, 72%, 75%, 80%,
25 85%, 87%, 90%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of SEQ ID NO:3, 6, 9, or 10.

In another preferred embodiment, a FRD3 protein includes at least one transmembrane domain belonging to the MATE family of molecules and has a FRD3 activity (as described herein).

30 In yet another preferred embodiment, a FRD3 protein includes at least one transmembrane domain belonging to the MATE family of molecules and is encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, 2, 4, 5, 7, 8, 20, or a complement thereof.

35 In another embodiment, the invention features fragments of the protein having the amino acid sequence of SEQ ID NO:3, 6, 9, or 10, wherein the fragment

comprises at least 15 amino acids (*e.g.*, contiguous amino acids) of the amino acid sequence of SEQ ID NO:3, 6, 9, or 10. In another embodiment, a FRD3 protein has the amino acid sequence of SEQ ID NO:3, 6, 9, or 10.

5 In another embodiment, the invention features a FRD3 protein which is encoded by a nucleic acid molecule consisting of a nucleotide sequence at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identical to a nucleotide sequence of SEQ ID NO:1, 2, 4, 5, 7, 8, 20, or a complement thereof. This invention further features a FRD3 protein which is encoded by a nucleic acid molecule consisting of a nucleotide sequence which hybridizes under stringent
10 hybridization conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, 2, 4, 5, 7, 8, 20, or a complement thereof.

The proteins of the present invention or portions thereof, *e.g.*, biologically active portions thereof, can be modified to alter FRD3 bioactivity, *e.g.*, to impart desired characteristics thereon, such as increased solubility, enhanced therapeutic
15 or prophylactic efficacy, or stability. Such modified peptides are considered functional equivalents of peptides having an activity of FRD3 as defined herein. A modified peptide can be produced in which the amino acid sequence has been altered, such as by amino acid substitution, deletion, or addition. In another embodiment, a component which imparts a desired characteristic on a peptide can be linked to the peptide to form a
20 modified peptide.

The proteins of the present invention or portions thereof, *e.g.*, biologically active portions thereof, can be operatively linked to a non-FRD3 polypeptide (*e.g.*, heterologous amino acid sequences) to form fusion proteins. The invention further features antibodies, such as monoclonal or polyclonal antibodies, that
25 specifically bind proteins of the invention, preferably FRD3 proteins. In addition, the FRD3 proteins or biologically active portions thereof can be incorporated into pharmaceutical compositions, which optionally include pharmaceutically acceptable carriers.

In another aspect, the present invention provides a method for detecting
30 the presence of a FRD3 nucleic acid molecule, protein, or polypeptide in a biological sample by contacting the biological sample with an agent capable of detecting a FRD3 nucleic acid molecule, protein, or polypeptide such that the presence of a FRD3 nucleic acid molecule, protein or polypeptide is detected in the biological sample.

In another aspect, the present invention provides a method for detecting
35 the presence of FRD3 activity in a biological sample by contacting the biological sample

with an agent capable of detecting an indicator of FRD3 activity such that the presence of FRD3 activity is detected in the biological sample.

In another aspect, the invention provides a method for modulating FRD3 activity comprising contacting a cell capable of expressing FRD3 with an agent that modulates FRD3 activity such that FRD3 activity in the cell is modulated. In one embodiment, the agent inhibits FRD3 activity. In another embodiment, the agent stimulates FRD3 activity. In one embodiment, the agent is an antibody that specifically binds to a FRD3 protein. In another embodiment, the agent modulates expression of FRD3 by modulating transcription of a *frd3* gene or translation of a *frd3* mRNA. In yet another embodiment, the agent is a nucleic acid molecule having a nucleotide sequence that is antisense to the coding strand of a *frd3* mRNA or a *frd3* gene. In yet another embodiment, the agent is a double stranded RNA molecule.

The invention also provides transgenic plants in which the expression of an FRD3 polypeptide is altered, as well as seeds and cells derived from such plants. For example, the invention includes a method for evaluating the effect of the expression or misexpression of a *frd3* gene on a parameter related to iron homeostasis. The method includes providing a transgenic plant having a *frd3* transgene, or which otherwise misexpresses a *frd3* gene, contacting the transgenic plant with an agent, and evaluating the effect of the transgene or misexpression of the *frd3* gene on the parameter related to iron homeostasis (*e.g.*, by comparing the value of the parameter for a transgenic plant with the value for a control).

In addition, the transgenic plant, *e.g.*, maize, wheat, rye, sorghum, cassava, beans, rice, beans, and peas, in which expression of a FRD3 polypeptide is altered can be incorporated into a pharmaceutical composition which includes the transgenic plant, or a portion thereof, and a pharmaceutically acceptable carrier. Such compositions can be used as human or animal nutritional supplements to provide, for example, iron to a subject with iron-deficiency or zinc to a subject with zinc-deficiency.

In another aspect the invention provides methods for identifying a compound that binds to or modulates the activity of a FRD3 protein, by providing an indicator composition comprising a FRD3 protein having FRD3 activity, contacting the indicator composition with a test compound, and determining the effect of the test compound on FRD3 activity in the indicator composition to identify a compound that modulates the activity of a FRD3 protein.

Methods for identifying an agent which inhibits or activates/stimulates a FRD3 polypeptide are also within the scope of the invention. These methods include contacting a first polypeptide comprising a naturally occurring ligand of FRD3, with a

second polypeptide comprising a FRD3 polypeptide and an agent to be tested and then determining binding of the second polypeptide to the first polypeptide. Inhibition of binding of the first polypeptide to the second polypeptide indicates that the agent is an inhibitor of a FRD3 polypeptide while activation/stimulation of binding of the first
5 polypeptide to the second polypeptide indicates that the agent is an activator/stimulator or a FRD3 polypeptide.

In another aspect, the invention features a method for evaluating a candidate compound for the ability to interact with a FRD3 polypeptide. This method includes contacting the compound with the FRD3 polypeptide and evaluating the ability
10 of the compound to interact with the FRD3 polypeptide. This method can be performed *in vitro* or *in vivo*.

The FRD3 polypeptides of the invention can be used to modulate metal concentrations *in vitro* or *in vivo*. In one aspect, the invention provides a method for modulating metal concentration in a biological sample containing the metal. This
15 method includes providing a transgenic plant in which expression of a FRD3 polypeptide is altered and contacting the transgenic plant with the biological sample such that the metal concentration in the biological sample is modulated.

The invention further provides methods for removing a pollutant from soil. These methods include contacting a transgenic plant in which expression of an
20 FRD3 polypeptide is altered with the soil such that the pollutant is removed from the soil. In a preferred embodiment, the pollutant is a metal, *e.g.*, a metal selected from the group consisting of Pb, As, Co, Cu, Zn, Cd and/or Hg.

Additional methods of the invention include methods for treating a disorder associated with metal-deficiency, *e.g.*, iron-deficiency or zinc-deficiency, in a
25 subject. These methods include administering to a subject a therapeutically effective amount of a composition comprising a transgenic plant, or a portion thereof, in which expression of a FRD3 polypeptide is altered. In a preferred embodiment, the composition is administered in combination with a pharmaceutically acceptable carrier. In other preferred embodiments, the FRD3 polypeptide in the transgenic plant is
30 overexpressed. In yet other preferred embodiments, the disorder associated with iron-deficiency is anemia.

Still additional methods of the invention include methods for promoting plant growth and/or survival. These methods include introducing into a plant a nucleic acid encoding a FRD3 polypeptide.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

Brief Description of the Figures

5

Figure 1a-1b depicts the cDNA sequence of *frd3-1* (SEQ ID NO:2).

Figure 2a-2b depicts the cDNA sequence of *frd3-2* (SEQ ID NO:5).

Figure 3a-3b depicts the cDNA sequence of *frd3-3* (SEQ ID NO:8).

10 Figure 4 depicts the amino acid sequences of wild type FRD3 (SEQ ID NO:10) with transmembrane domains shown in bold, FRD3-1 (SEQ ID NO:3), FRD3-2 (SEQ ID NO:6), and FRD3-3 (SEQ ID NO:9).

Figure 5a-5e depicts the genomic sequence of *frd3-1* (SEQ ID NO:1).

Figure 6a-6e depicts the genomic sequence of *frd3-2* (SEQ ID NO:4).

15 Figure 7a-7e depicts the genomic sequence of *frd3-3* (also referred to herein as *man1*) (SEQ ID NO:7).

Figure 8 includes are graphs (A) and (B) showing ferric chelate reductase activity. (A) *frd3* and *man1* exhibit constitutive Fe(III) chelate reductase activity. Plants grown with or without Fe(III) EDTA for three days were assayed for Fe(III) chelate reductase activity. (B) *frd3* and *man1* are recessive and allelic. All plants were grown
20 with Fe(III) EDTA for three days. For both panels, values are the mean of nine (9) plants and standard errors are shown. Experiments were performed at least twice and representative data sets are shown.

Figure 9 is a bar graph showing *frd3* alleles accumulate more Fe, Mn and Zn in their shoots. Pooled samples of two week old shoots from plants grown on B5
25 plates were subjected to elemental analysis. This experiment was repeated and similar results obtained.

Figure 10 shows the positional cloning and structure of the wild type *frd3* gene.

(A) The region of Chromosome 3 containing *frd3*. The chromosome is
30 depicted by the uppermost horizontal line with the flanking markers C6 and g4119. Below that are three BACs from the AGI minimal tiling path: MLP3, F17A17, and T8G24. Markers (see Materials and Methods), the number of recombinant chromosomes out of the 1640 examined, and the final 55 kb interval containing *frd3* are shown below. The striped bar indicates the segment of genomic DNA used to
35 complement *frd3-1*.

(B) Complementation of *frd3-1*. An 11 kb segment of genomic DNA, when expressed in *frd3-1*, restores the repression of Fe(III) chelate reductase activity in plants grown for three days in the presence of Fe(III) EDTA. Values are the mean of nine individual plants and error bars depict standard error.

5 (C) Predicted topology of the FRD3 protein. The 12 transmembrane domains, as predicted by HMMTOP, and the location and nature of the mutations carried by the three mutant alleles are shown.

(D) Intron/exon structure of *frd3*. The narrow lines depict intron sequences and broader lines, exon sequences. The broad, filled line corresponds to the open reading frame and the broad open line to the 5' and 3' untranslated regions. Line
10 lengths are approximately to scale.

Figure 11 is a bar graph showing wild type *frd3* expression levels depend on iron status and genotype. The RNA blot used in Figure 9 was re-probed with *frd3*. The expression level of *frd3* was normalized to *UBQ5* and is shown in arbitrary units.
15 Results are presented as a graph to emphasize the very large differences in expression levels. Values are the mean of three replicate experiments and error bars indicate standard error.

Figure 12 is a dendrogram showing amino acid sequence similarity relationships among selected MATE family members. Multiple sequence alignments
20 were performed using the BCM Search Launcher and the dendrogram using MEGA 2.1. Bootstrap values are shown next to each junction.

Figure 13 is an alignment of the amino acid sequences of selected MATE family members. Identical residues are on a black background and conservative substitutions on gray. Lines depict FRD3 transmembrane domains as predicted by
25 HMMTOP. Multiple sequence alignments were performed using the BCM Search Launcher and residue shading using BoxShade 3.21.

Figure 14a-14b depicts the cDNA sequence of *frd3* (SEQ ID NO:20).

Detailed Description of the Invention

30 This invention is based, at least in part, on the discovery of the functional characteristics of the wild type ferric reductase defective (FRD3) nucleic acid and protein molecules and the discovery of mutant FRD3 molecules. Designated herein as "FRD3 nucleic acid and protein molecules," this novel group of molecules belongs to the multi-drug and toxin efflux (MATE) family, and includes, for example, FRD3 molecules
35 such as FRD3, FRD3-1, FRD3-2, and FRD3-3 (FRD3-3 is also referred to herein as MAN1) molecules.

Wild type FRD3 nucleic acid and protein molecules, such as FRD3, are expressed in plants under metal deficient conditions, *e.g.*, iron deficient conditions, and are capable of increasing metal uptake in plants under such conditions and decreasing metal uptake in plants under metal sufficient conditions. In contrast, mutant FRD3 nucleic acid and protein molecules, such as FRD3-1, FRD3-2, and FRD3-3, are expressed under both metal sufficient and metal deficient conditions which results in an increase of metal uptake in plants under both metal sufficient and deficient conditions. Accordingly, wild type FRD3 and mutant FRD3 nucleic acid and protein molecules are useful as modulating agents in regulating metal homeostasis, *e.g.*, iron homeostasis.

The *frd3* gene was identified in the plant *Arabidopsis thaliana*. *Arabidopsis thaliana*, a common wall cress, is a small member of the mustard or crucifer family. *frd3* encodes an integral membrane protein 526 amino acid residues long which contains approximately ten to twelve transmembrane domains and may act as a regulatory factor involved in sensing and/or responding to iron levels *frd3*. The mutant alleles of the *frd3* gene, *i.e.*, additional members of the FRD3 family, designated herein as *frd3-1*, *frd3-2*, and *frd3-3*, possess single base pair alterations in a single open reading frame compared to the wild type *frd3* gene.

The FRD3 nucleic acid and protein molecules share several structural/functional properties. Structurally, FRD3 polypeptides are expressed in the roots but not in shoots of plants and include, for example, at least one transmembrane domain belonging to the MATE family of molecules (Brown *et al.*, Mol. Micro., 31:393, 1999), preferably approximately ten to twelve transmembrane domains. Functionally, FRD3 nucleic acid and protein molecules are capable of, for example, expressing metal deficiency responses, *e.g.*, iron deficiency responses. In particular, wild type FRD3 molecules are capable of increasing metal uptake in plants under metal deficient conditions and decreasing metal uptake in plants under metal sufficient conditions. Mutant FRD3 molecules, *e.g.*, FRD3-1, FRD3-2, and FRD3-3, are capable of expressing metal deficiency responses under both metal deficient and metal sufficient conditions. Mutant FRD3 molecules are also capable of, (1) misexpressing ferric chelate reductase activity, (2) overaccumulating metals, *e.g.*, iron, or (3) causing chlorosis. In particular, while not intending to be limited to any theory, it is believed that the FRD3 nucleic acid and protein molecules serve as a receptor for metal deficiency signals, for example, a receptor for iron deficiency signals. Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding FRD3 proteins or biologically active portions thereof, as well as nucleic acid fragments suitable as primers or hybridization probes for the detection of *frd3*-encoding nucleic acids.

As used herein, the term “multi-drug and toxin efflux” or “MATE” includes a molecule which is involved in a variety of processes by functioning as a transporter of small organic molecules. As a subset of the MATE family of molecules, the terms “ferric reductase defective,” “FRD3,” or “mutant FRD3” include molecules which serves as a receptor for metal deficiency signals, for example, a receptor for iron deficiency signals. Accordingly, FRD3 nucleic acid and protein molecules are capable of modulating metal concentrations. Bioactivity associated with FRD3 molecules, or “FRD3 activity,” includes, for example, the expression of metal deficiency responses, *e.g.*, iron deficiency responses. Mutant FRD3 molecules are also capable of (1) misexpressing ferric chelate reductase activity, (2) overaccumulating metals, *e.g.*, iron, or (3) causing chlorosis. As modulators of metal concentrations, FRD3 molecules of the present invention provide novel diagnostic targets and therapeutic agents to control a variety of disorders relating to metal deficiency, *e.g.*, iron deficiency or anemia. FRD3 molecules of the present invention also provide novel tools for promoting plant growth and/or survival and for removing pollutants from soil.

The term “family” when referring to the protein and nucleic acid molecules of the invention is intended to mean two or more proteins or nucleic acid molecules having a common structural domain or motif and having sufficient amino acid or nucleotide sequence homology as defined herein. Such family members can be naturally or non-naturally occurring and can be from either the same or different species. For example, a family can contain a first protein of human origin, as well as other, distinct proteins of human origin or alternatively, can contain homologues of non-human origin, *e.g.*, monkey proteins. Members of a family may also have common functional characteristics.

For example, the family of FRD3 proteins comprises at least one transmembrane domain belonging to the MATE family of molecules in the protein or corresponding nucleic acid molecule. In a preferred embodiment, FRD3 molecules comprise at least about 3, 6, 9, 10, 11, 12, or more transmembrane domains belonging to the MATE family of molecules.

As used herein, the term “transmembrane domain” includes an amino acid sequence of about 15 amino acid residues in length which spans the plasma membrane. More preferably, a transmembrane domain includes about at least 5, 10, 12, 15, 20, 25, 30, 35, 40, or 45 amino acid residues and spans the plasma membrane. Transmembrane domains are rich in hydrophobic residues, and typically have an alpha-helical structure. In a preferred embodiment, at least 50%, 60%, 70%, 80%, 90%, 95% or more of the amino acids of a transmembrane domain are hydrophobic, *e.g.*, leucines,

isoleucines, tyrosines, or tryptophans. Transmembrane domains are described in, for example, Zagotta W.N. *et al.*, (1996) *Annual Rev. Neurosci.* 19: 235-263, the contents of which are incorporated herein by reference. As shown in Figure 4, transmembrane domains of FRD3 correspond to the transmembrane domains found in the wild type

5 FRD3 polypeptide which include, for example, amino acid residues 37-57, 61-80, 173-197, 215-237, 245-267, 272-294, 316-339, 355-379, 395-419, 423-447, 452-476, and 485-504 of SEQ ID NO: 10. Accordingly, FRD3 proteins having at least 50-60% homology, preferably about 60-70%, more preferably about 70-80%, or about 80-90% homology with a transmembrane domain of FRD3 are within the scope of the invention.

10 Isolated proteins of the present invention, preferably FRD3 proteins, have an amino acid sequence sufficiently identical to the amino acid sequence of SEQ ID NO:3, 6, 9, or 10, or are encoded by a nucleotide sequence sufficiently identical to SEQ ID NO:1, 2, 4, 5, 7, 8, or 20. As used herein, the term "sufficiently identical" refers to a

15 of identical or equivalent (*e.g.*, an amino acid residue which has a similar side chain) amino acid residues or nucleotides to a second amino acid or nucleotide sequence such that the first and second amino acid or nucleotide sequences share common structural domains or motifs and/or a common functional activity. For example, amino acid or nucleotide sequences which share common structural domains have at least 30%, 40%,

20 or 50% homology, preferably 60% homology, more preferably 70%-80%, and even more preferably 90-95% homology across the amino acid sequences of the domains and contain at least one and preferably two structural domains or motifs, are defined herein as sufficiently identical. Furthermore, amino acid or nucleotide sequences which share

25 at least 30%, 40%, or 50%, preferably 60%, more preferably 70-80%, or 90-95% homology and share a common functional activity are defined herein as sufficiently identical.

As used interchangeably herein, a "FRD3 activity", "biological activity of FRD3" or "FRD3-mediated activity," includes an activity exerted by a FRD3 protein, polypeptide or nucleic acid molecule on a FRD3 responsive cell or tissue, or on a FRD3

30 protein substrate, as determined *in vivo*, or *in vitro*, according to standard techniques. In one embodiment, a FRD3 activity is a direct activity, such as an association with a FRD3 target molecule. As used herein, a "target molecule" or "binding partner" is a molecule with which a FRD3 protein binds or interacts in nature, such that FRD3 mediated function is achieved. A FRD3 target molecule can be a non-FRD3 molecule or

35 a FRD3 protein or polypeptide of the present invention. In an exemplary embodiment, a FRD3 target molecule is a FRD3 substrate (*e.g.*, a peptide). Alternatively, a FRD3

activity is an indirect activity, such as a cellular signaling activity mediated by interaction of the FRD3 protein with a FRD3 ligand or substrate. The biological activities of FRD3 are described herein. For example, the FRD3 proteins of the present invention can have one or more of the following activities: (1) the expression of metal deficiency, *e.g.*, iron deficiency, responses under conditions of metal sufficiency or metal deficiency, (2) the misexpression of ferric chelate reductase activity, (3) the overaccumulation of metals, *e.g.*, iron, or (4) chlorosis.

Accordingly, another embodiment of the invention features isolated FRD3 proteins and polypeptides having a FRD3 activity. Other preferred proteins are FRD3 proteins having at least one transmembrane domain and, preferably, a FRD3 activity.

Additional preferred proteins have at least one transmembrane domain and are, preferably, encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, 3, 4, 6, 8, 9, or a complement thereof.

Various aspects of the invention are described in further detail in the following subsections:

I. Isolated *frd3* Nucleic Acid Molecules

One aspect of the invention pertains to isolated nucleic acid molecules that encode FRD3 proteins or biologically active portions thereof, as well as nucleic acid fragments sufficient for use as hybridization probes to identify *frd3*-encoding nucleic acid molecules (*e.g.*, *frd3* mRNA) and fragments for use as PCR primers for the amplification or mutation of *frd3* nucleic acid molecules. As used herein, the term “nucleic acid molecule” is intended to include DNA molecules (*e.g.*, cDNA or genomic DNA) and RNA molecules (*e.g.*, mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.

The term “isolated nucleic acid molecule” includes nucleic acid molecules which are separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. For example, with regards to genomic DNA, the term “isolated” includes nucleic acid molecules which are separated from the chromosome with which the genomic DNA is naturally associated. Preferably, an “isolated” nucleic acid is free of sequences which naturally flank the nucleic acid (*i.e.*, sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the

organism from which the nucleic acid is derived. For example, in various embodiments, the isolated *frd3* nucleic acid molecule can contain less than about 5 kb, 4kb, 3kb, 2kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an “isolated” nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the present invention, *e.g.*, a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1, 2, 4, 5, 7, 8, 20, or a portion thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or portion of the nucleic acid sequence of SEQ ID NO: 1, 2, 4, 5, 7, 8, or 20, as a hybridization probe, *frd3* nucleic acid molecules can be isolated using standard hybridization and cloning techniques (*e.g.*, as described in Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A., and Struhl, K. (2002) Current Protocols in Molecular Biology. (New York, NY: John Wiley & Sons).

Moreover, a nucleic acid molecule encompassing all or a portion of SEQ ID NO: 1, 2, 4, 5, 7, 8, or 20, can be isolated by the polymerase chain reaction (PCR) using synthetic oligonucleotide primers designed based upon the sequence of SEQ ID NO: 1, 2, 4, 5, 7, 8, or 20.

A nucleic acid of the invention can be amplified using cDNA, mRNA or, alternatively, genomic DNA as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to *frd3* nucleotide sequences can be prepared by standard synthetic techniques, *e.g.*, using an automated DNA synthesizer.

In a preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO: 1, 2, 4, 5, 7, 8, or 20. This cDNA may comprise sequences encoding the FRD3 protein, *i.e.*, “the coding region,” from nucleotides 118-1698 of SEQ ID NO:2, nucleotides 118-1182 of SEQ ID NO:5, nucleotides 118-870 of SEQ ID NO:8, or nucleotides 118-1698 of SEQ ID NO:20, as well as 5’ untranslated sequences (nucleotides 1-117 of SEQ ID NOs:2, 5, 8, or 20) and 3’ untranslated sequences (nucleotides 1699-1868 of SEQ ID NO:2, nucleotides 1183-1867 of SEQ ID NO:5, nucleotides 871-1950 of SEQ ID NO:8, or nucleotides 1699-11868 of SEQ ID NO:20). Alternatively, the nucleic acid molecule can comprise only the coding region of SEQ ID NO:2, 5, or 8 (*e.g.*, nucleotides 118-1698

of SEQ ID NO:2, nucleotides 118-1182 of SEQ ID NO:5, nucleotides 118-870 of SEQ ID NO:8, or nucleotides 118-1698 of SEQ ID NO:20).

In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of the nucleotide
5 sequence shown in SEQ ID NO:1, 2, 4, 5, 7, 8, or 20, or a portion of any of these nucleotide sequences. A nucleic acid molecule which is complementary to the nucleotide sequence shown in SEQ ID NO: 1, 2, 4, 5, 7, 8, or 20, is one which is sufficiently complementary to the nucleotide sequence shown in SEQ ID NO: 1, 2, 4, 5, 7, 8, or 20, such that it can hybridize to the nucleotide sequence shown in SEQ ID NO:
10 1, 2, 4, 5, 7, 8, or 20, respectively, thereby forming a stable duplex.

In still another preferred embodiment, an isolated nucleic acid molecule of the present invention comprises a nucleotide sequence which is at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identical to the entire length of the nucleotide sequence shown in SEQ ID NO: 1, 2, 4, 5,
15 7, 8, or 20, or a portion of any of these nucleotide sequences.

Moreover, the nucleic acid molecule of the invention can comprise only a portion of the nucleic acid sequence of SEQ ID NO: 1, 2, 4, 5, 7, 8, or 20, for example, a fragment which can be used as a probe or primer or a fragment encoding a portion of a FRD3 protein, *e.g.*, a biologically active portion of a FRD3 protein. The nucleotide
20 sequences determined from the cloning of *frd3* genes allow for the generation of probes and primers designed for use in identifying and/or cloning other FRD3 family members, as well as FRD3 homologues from other species. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12 or
25 15, preferably about 20 or 25, more preferably about 30, 35, 40, 45, 50, 55, 60, 65, or 75 consecutive nucleotides of a sense sequence of SEQ ID NO: 1, 2, 4, 5, 7, 8, or 20, of an anti-sense sequence of SEQ ID NO: 1, 2, 4, 5, 7, 8, or 20, or of a naturally occurring allelic variant or mutant of SEQ ID NO: 1, 2, 4, 5, 7, 8, or 20. In one embodiment, a nucleic acid molecule of the present invention comprises a nucleotide sequence which is
30 greater than 50-100, 100-150, 150-200, 200-250, 250-300, 300-350, 350-400, 400-450, 450-500, 500-550, 550-600, 600-650, 653, 653-700, 700-750, 750-800, 800-850, 850-900, 900-950, 950-1000, 1000-1050, 1050-1100, 1100-1150, 1150-1200, 1200-1250, 1250-1300, 1300-1350, 1350-1400, 1400-1450, 1450-1500, 1500-1550, 1550-1600, 1600-1650, 1650-1700, 1700-1750 or more nucleotides in length and hybridizes under
35 stringent hybridization conditions to a nucleic acid molecule of SEQ ID NO: 1, 2, 4, 5, 7, 8, or 20.

Probes based on the *frd3* nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In preferred embodiments, the probe further comprises a label group attached thereto, *e.g.*, the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissue which misexpress a FRD3 protein, such as by measuring a level of a *frd3*-encoding nucleic acid in a sample of cells from a subject *e.g.*, detecting *frd3* mRNA levels or determining whether a genomic *frd3* gene has been mutated or deleted.

A nucleic acid fragment encoding a “biologically active portion of a FRD3 protein” can be prepared by isolating a portion of the nucleotide sequence of SEQ ID NO: 1, 2, 4, 5, 7, 8, or 20 which encodes a polypeptide having a FRD3 biological activity (the biological activities of the FRD3 proteins are described herein), expressing the encoded portion of the FRD3 protein (*e.g.*, by recombinant expression *in vitro*) and assessing the activity of the encoded portion of the FRD3 protein. Biologically active portions of a FRD3 protein can be identified, for example, by a ferric chelate reductase assay (Yi and Guerinot (1996) Plant J. 10:835-844).

The invention further encompasses nucleic acid molecules that differ from the nucleotide sequence shown in SEQ ID NO: 1, 2, 4, 5, 7, 8, or 20 due to degeneracy of the genetic code and thus encode the same FRD3 proteins as those encoded by the nucleotide sequence shown in SEQ ID NO: 1, 2, 4, 5, 7, 8, or 20. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in SEQ ID NO: 3, 6, 9, or 10.

In addition to the *frd3* nucleotide sequences shown in SEQ ID NO: 1, 2, 4, 5, 7, 8, or 20, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the FRD3 proteins may exist within a population (*e.g.*, a plant population). Such genetic polymorphism in the *frd3* genes may exist within a population due to natural allelic variation. As used herein, the terms “gene” and “recombinant gene” refer to nucleic acid molecules which include an open reading frame encoding a FRD3 protein, preferably an *Arabidopsis* FRD3 protein, and can further include non-coding regulatory sequences, and introns.

Allelic variants of FRD3 include both functional and non-functional FRD3 proteins. Functional allelic variants are naturally occurring amino acid sequence variants of the FRD3 protein that retain FRD3-mediated activity. Functional allelic variants will typically contain only conservative substitution of one or more amino acids

of SEQ ID NO:3, 6, 9, or 10, or substitution, deletion or insertion of non-critical residues in non-critical regions of the protein.

Non-functional allelic variants are naturally occurring amino acid sequence variants of the FRD3 protein that do not retain FRD3-mediated activity as described herein. Non-functional allelic variants will typically contain a non-conservative substitution, a deletion, or insertion or premature truncation of the amino acid sequence of SEQ ID NO:3, 6, 9, or 10, or a substitution, insertion or deletion in critical residues or critical regions of the protein.

The present invention further provides human orthologues of the FRD3 protein. Orthologues of the FRD3 protein are proteins that are isolated from human organisms and possess the same FRD3 activities of the FRD3 protein. Orthologues of the FRD3 protein can readily be identified as comprising an amino acid sequence that is substantially identical to SEQ ID NO:3, 6, 9, or 10.

Moreover, nucleic acid molecules encoding other FRD3 family members and, thus, which have a nucleotide sequence which differs from the *frd3* sequence of SEQ ID NO: 1, 2, 4, 5, 7, 8, or 20, are intended to be within the scope of the invention. For example, other *frd3* cDNAs can be identified based on the nucleotide sequences of *frd3*. Moreover, nucleic acid molecules encoding FRD3 proteins from different species, and which, thus, have a nucleotide sequence which differs from the *frd3* sequence of SEQ ID NO: 1, 2, 4, 5, 7, 8, or 20 are intended to be within the scope of the invention. For example, a genomic library from several other dicots, *e.g.*, tomato, broccoli or mustard, can be screened to obtain genes of the FRD3 family. Positive clones are then analyzed and sequenced to obtain additional family members.

Nucleic acid molecules corresponding to natural allelic variants and homologues of the *frd3* cDNAs of the invention can be isolated based on their homology to the *frd3* nucleic acids disclosed herein using the cDNAs disclosed herein, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions. Nucleic acid molecules corresponding to natural allelic variants and homologues of the *frd3* cDNAs of the invention can further be isolated by mapping to the same chromosome or locus as the *frd3* genes.

Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 15, 20, 25, 30 or more nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1, 2, 4, 5, 7, 8, or 20. In other embodiment, the nucleic acid is at least 50-100, 100-150, 150-200, 200-250, 250-300, 300-350, 350-400, 400-450, 450-500, 500-550, 550-600, 600-650, 650-700, 700-750, 750-800, 800-850, 850-900, 900-950, 950-

1000, 1000-1050, 1050-1100, 1100-1150, 1150-1200, 1200-1250, 1250-1300, 1300-1350, 1350-1400, 1400-1450, 1450-1500, 1500-1550, 1550-1600, 1600-1650, 1650-1700, 1700-1750 or more nucleotides in length.

As used herein, the term “hybridizes under stringent conditions” is
5 intended to describe conditions for hybridization and washing under which nucleotide sequences that are significantly identical or homologous to each other remain hybridized to each other. Preferably, the conditions are such that sequences at least about 70%, more preferably at least about 80%, even more preferably at least about 85% or 90% identical to each other remain hybridized to each other. Such stringent
10 conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, Ausubel *et al.*, eds., John Wiley & Sons, Inc. (2002), sections 2, 4 and 6. Additional stringent conditions can be found in *Molecular Cloning: A Laboratory Manual*, Sambrook *et al.*, Cold Spring Harbor Press, Cold Spring Harbor, NY (1989), chapters 7, 9 and 11. A preferred, non-limiting example of stringent
15 hybridization conditions includes hybridization in 4X sodium chloride/sodium citrate (SSC), at about 65-70°C (or hybridization in 4X SSC plus 50% formamide at about 42-50°C) followed by one or more washes in 1X SSC, at about 65-70°C. A preferred, non-limiting example of highly stringent hybridization conditions includes hybridization in 1X SSC, at about 65-70°C (or hybridization in 1X SSC plus 50% formamide at about
20 42-50°C) followed by one or more washes in 0.3X SSC, at about 65-70°C. A preferred, non-limiting example of reduced stringency hybridization conditions includes hybridization in 4X SSC, at about 50-60°C (or alternatively hybridization in 6X SSC plus 50% formamide at about 40-45°C) followed by one or more washes in 2X SSC, at about 50-60°C. Ranges intermediate to the above-recited values, *e.g.*, at 65-70°C or at
25 42-50°C are also intended to be encompassed by the present invention. SSPE (1x SSPE is 0.15M NaCl, 10 mM NaH₂PO₄, and 1.25 mM EDTA, pH 7.4) can be substituted for SSC (1x SSC is 0.15M NaCl and 15 mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes each after hybridization is complete. The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length
30 should be 5-10 °C less than the melting temperature (T_m) of the hybrid, where T_m is determined according to the following equations. For hybrids less than 18 base pairs in length, $T_m(^{\circ}\text{C}) = 2(\# \text{ of A} + \text{T bases}) + 4(\# \text{ of G} + \text{C bases})$. For hybrids between 18 and 49 base pairs in length, $T_m(^{\circ}\text{C}) = 81.5 + 16.6(\log_{10} [\text{Na}^+]) + 0.41(\% \text{ G} + \text{C}) - (600/\text{N})$, where N is the number of bases in the hybrid, and $[\text{Na}^+]$ is the concentration of sodium
35 ions in the hybridization buffer ($[\text{Na}^+]$ for 1x SSC = 0.165 M). It will also be recognized by the skilled practitioner that additional reagents may be added to hybridization and/or

wash buffers to decrease non-specific hybridization of nucleic acid molecules to membranes, for example, nitrocellulose or nylon membranes, including but not limited to blocking agents (*e.g.*, BSA or salmon or herring sperm carrier DNA), detergents (*e.g.*, SDS), chelating agents (*e.g.*, EDTA), Ficoll, PVP and the like. When using nylon
5 membranes, in particular, an additional preferred, non-limiting example of stringent hybridization conditions is hybridization in 0.25-0.5M NaH₂PO₄, 7% SDS at about 65 °C, followed by one or more washes at 0.02M NaH₂PO₄, 1% SDS at 65 °C, see *e.g.*, Church and Gilbert (1984) *Proc. Natl. Acad. Sci. USA* 81:1991-1995, (or, alternatively, 0.2X SSC, 1% SDS).

10 In addition to naturally-occurring allelic variants of the FRD3 sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences of SEQ ID NO: 1, 2, 4, 5, 7, 8, or 20, thereby leading to changes in the amino acid sequence of the encoded FRD3 proteins, without altering the functional ability of the FRD3 proteins. For example,
15 nucleotide substitutions leading to amino acid substitutions at “non-essential” amino acid residues can be made in the sequence of SEQ ID NO: 1, 2, 4, 5, 7, 8, or 20. A “non-essential” amino acid residue is a residue that can be altered from FRD3 sequences (*e.g.*, the sequence of SEQ ID NOs:3, 6, 9, or 10) without altering the biological activity thereof, whereas an “essential” amino acid residue is required for biological activity. For
20 example, amino acid residues that are conserved among the FRD3 proteins of the present invention, *e.g.*, those present in a transmembrane domain, are predicted to be particularly unamenable to alteration. Furthermore, additional amino acid residues that are conserved between the FRD3 proteins of the present invention and other members of the FRD3 family are not likely to be amenable to alteration.

25 Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding FRD3 proteins that contain changes in amino acid residues that are not essential for activity. Such FRD3 proteins differ in amino acid sequence from SEQ ID NO:3, 6, 9, or 10, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the
30 protein comprises an amino acid sequence at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO:3, 6, 9, or 10.

An isolated nucleic acid molecule encoding a FRD3 protein identical to the protein of SEQ ID NO:3, 6, 9, or 10 can be created by introducing one or more
35 nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO: 1, 2, 4, 5, 7, 8, or 20 such that one or more amino acid substitutions, additions or

deletions are introduced into the encoded protein. Mutations can be introduced into SEQ ID NO: 1, 2, 4, 5, 7, 8, or 20 by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (*e.g.*, threonine, valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in a FRD3 protein is preferably replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a *frd3* coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for FRD3 biological activity to identify mutants that retain activity. Following mutagenesis of SEQ ID NO: 1, 2, 4, 5, 7, 8, or 20, the encoded protein can be expressed recombinantly and the activity of the protein can be determined.

In a preferred embodiment, a mutagenized FRD3 protein can be assayed for the ability to: (1) express metal deficiency responses, *e.g.*, iron deficiency responses, under conditions of metal sufficiency, (2) misexpress ferric chelate reductase activity, (3) overaccumulate metals, *e.g.*, iron, or (4) cause chlorosis.

In addition to the nucleic acid molecules encoding FRD3 proteins described above, another aspect of the invention pertains to isolated nucleic acid molecules which are antisense thereto. An “antisense” nucleic acid comprises a nucleotide sequence which is complementary to a “sense” nucleic acid encoding a protein, *e.g.*, complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid. The antisense nucleic acid can be complementary to an entire *frd3* coding strand, or to only a portion thereof. In one embodiment, an antisense nucleic acid molecule is antisense to a “coding region” of the coding strand of a nucleotide sequence encoding *frd3*. The term “coding region” refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues (*e.g.*, the coding region of *frd3-1* corresponds to nucleotides 118-1698 of SEQ ID NO:2, the coding region of *frd3-2* corresponds to nucleotides 118-1182 of SEQ ID NO:5, and

the coding region of *frd3-3* corresponds to nucleotides 118-870 of SEQ ID NO:8). In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding FRD3 polypeptides. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (*i.e.*, also referred to as 5' and 3' untranslated regions).

Given the coding strand sequences encoding FRD3 polypeptides disclosed herein, antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of *frd3* mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of *frd3* mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of *frd3* mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (*e.g.*, an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, *e.g.*, phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5- oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (*i.e.*, RNA transcribed from the

inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

Another aspect of the invention pertains to double stranded RNA comprising *frd3*-specific sequences in the sense and antisense orientations and capable of duplex formation with *frd3* genes. As further described in Chuang and Meryerowitz (2000) PNAS 97(9):4985-4990, such double stranded RNA can be used to mediate interference with the expression of certain genes.

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a FRD3 protein to thereby inhibit expression of the protein, *e.g.*, by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention include direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, *e.g.*, by linking the antisense nucleic acid molecules to peptides or antibodies which bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an α -anomeric nucleic acid molecule. An α -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other (Gaultier *et al.* (1987) *Nucleic Acids. Res.* 15:6625-6641). The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (Inoue *et al.* (1987) *Nucleic Acids Res.* 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue *et al.* (1987) *FEBS Lett.* 215:327-330).

In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (*e.g.*, hammerhead ribozymes

(described in Haselhoff and Gerlach (1988) *Nature* 334:585-591)) can be used to catalytically cleave *frd3* mRNA transcripts to thereby inhibit translation of *frd3* mRNA. A ribozyme having specificity for a *frd3*-encoding nucleic acid can be designed based upon the nucleotide sequence of a *frd3* cDNA disclosed herein (*i.e.*, SEQ ID NO: 3).

- 5 For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a *frd3*-encoding mRNA. See, *e.g.*, Cech *et al.* U.S. Patent No. 4,987,071; and Cech *et al.* U.S. Patent No. 5,116,742. Alternatively, *frd3* mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA
10 molecules. See, *e.g.*, Bartel, D. and Szostak, J.W. (1993) *Science* 261:1411-1418.

- Alternatively, *frd3* gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of *frd3* nucleic acid molecules to form triple helical structures that prevent transcription of a *frd3* gene in target cells. See generally, Helene, C. (1991) *Anticancer Drug Des.* 6(6): 569-84;
15 Helene, C. *et al.* (1992) *Ann. N.Y. Acad. Sci.* 660:27-36; and Maher, L.J. (1992) *Bioassays* 14(12):807-15.

- In yet another embodiment, the *frd3* nucleic acid molecules of the present invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, *e.g.*, the stability, hybridization, or solubility of the molecule. For example, the
20 deoxyribose phosphate backbone of the nucleic acid molecules can be modified to generate peptide nucleic acids (see Hyrup B. *et al.* (1996) *Bioorganic & Medicinal Chemistry* 4 (1): 5-23). As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics, *e.g.*, DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases
25 are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup B. *et al.* (1996) *supra*; Perry-O'Keefe *et al.* *Proc. Natl. Acad. Sci.* 93: 14670-675.

- 30 PNAs of *frd3* nucleic acid molecules can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, for example, inducing transcription or translation arrest or inhibiting replication. PNAs of *frd3* nucleic acid molecules can also be used in the analysis of single base pair mutations in a gene, (*e.g.*,
35 by PNA-directed PCR clamping); as 'artificial restriction enzymes' when used in combination with other enzymes, (*e.g.*, S1 nucleases (Hyrup B. (1996) *supra*)); or as

probes or primers for DNA sequencing or hybridization (Hyrup B. *et al.* (1996) *supra*; Perry-O'Keefe *supra*).

In another embodiment, PNAs of FRD3 can be modified, (*e.g.*, to enhance their stability or cellular uptake), by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of *frd3* nucleic acid molecules can be generated which may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, (*e.g.*, RNase H and DNA polymerases), to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup B. (1996) *supra*). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup B. (1996) *supra* and Finn P.J. *et al.* (1996) *Nucleic Acids Res.* 24 (17): 3357-63. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry and modified nucleoside analogs, *e.g.*, 5'-(4-methoxytrityl)amino-5'-deoxythymidine phosphoramidite, can be used as a between the PNA and the 5' end of DNA (Mag, M. *et al.* (1989) *Nucleic Acid Res.* 17: 5973-88). PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn P.J. *et al.* (1996) *supra*). Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment (Peterser, K.H. *et al.* (1975) *Bioorganic Med. Chem. Lett.* 5: 1119-11124).

In other embodiments, the oligonucleotide may include other appended groups such as peptides (*e.g.*, for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, *e.g.*, Letsinger *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86:6553-6556; Lemaitre *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:648-652; PCT Publication No. W088/09810) or the blood-brain barrier (see, *e.g.*, PCT Publication No. W089/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (See, *e.g.*, Krol *et al.* (1988) *Bio-Techniques* 6:958-976) or intercalating agents. (See, *e.g.*, Zon (1988) *Pharm. Res.* 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, (*e.g.*, a peptide, hybridization triggered cross-linking agent, transport agent, or hybridization-triggered cleavage agent).

Alternatively, the expression characteristics of an endogenous *frd3* gene within a cell line or microorganism may be modified by inserting a heterologous DNA regulatory element into the genome of a stable cell line or cloned microorganism such

that the inserted regulatory element is operatively linked with the endogenous *frd3* gene. For example, an endogenous *frd3* gene which is normally "transcriptionally silent", *i.e.*, a *frd3* gene which is normally not expressed, or is expressed only at very low levels in a cell line or microorganism, may be activated by inserting a regulatory element which is capable of promoting the expression of a normally expressed gene product in that cell line or microorganism. Alternatively, a transcriptionally silent, endogenous *frd3* gene may be activated by insertion of a promiscuous regulatory element that works across cell types.

A heterologous regulatory element may be inserted into a stable cell line or cloned microorganism, such that it is operatively linked with an endogenous *frd3* gene, using techniques, such as targeted homologous recombination, which are well known to those of skill in the art, and described, *e.g.*, in Chappel, U.S. Patent No. 5,272,071; PCT publication No. WO 91/06667, published May 16, 1991.

II. Isolated FRD3 Proteins and Anti-FRD3 Antibodies

One aspect of the invention pertains to isolated FRD3 proteins, and biologically active portions thereof, as well as polypeptide fragments suitable for use as immunogens to raise anti-FRD3 antibodies. In one embodiment, native FRD3 proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, FRD3 proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, a FRD3 protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the FRD3 protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of FRD3 protein in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. In one embodiment, the language "substantially free of cellular material" includes preparations of FRD3 protein having less than about 30% (by dry weight) of non-FRD3 protein (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-FRD3 protein, still more preferably less than about 10% of non-FRD3 protein, and most preferably less than about 5% non-FRD3 protein. When the FRD3 protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, *i.e.*, culture medium

represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of FRD3 protein in which the protein is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of FRD3 protein having less than about 30% (by dry weight) of chemical precursors or non-FRD3 chemicals, more preferably less than about 20% chemical precursors or non-FRD3 chemicals, still more preferably less than about 10% chemical precursors or non-FRD3 chemicals, and most preferably less than about 5% chemical precursors or non-FRD3 chemicals.

As used herein, a "biologically active portion" of a FRD3 protein includes a fragment of a FRD3 protein which participates in an interaction between a FRD3 molecule and a non-FRD3 molecule. Biologically active portions of a FRD3 protein include peptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of the FRD3 protein, *e.g.*, the amino acid sequence shown in SEQ ID NO:3, 6, 9, or 10, which include less amino acids than the full length FRD3 protein, and exhibit at least one activity of a FRD3 protein. Typically, biologically active portions comprise a domain or motif with at least one activity of the FRD3 protein, *e.g.*, modulation of metal concentrations. A biologically active portion of a FRD3 protein can be a polypeptide which is, for example, 25, 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1000, 1025, 1050, 1075, 1100, 1125, 1150, 1175, 1200, 1225, 1250, 1275, 1300, 1325, 1350, 1375, 1400, 1425, 1450, 1475, 1500, 1525, 1550, 1575, 1600, 1625, 1650, 1675, 1700, 1725, 1750, 1775 or more amino acids in length. Biologically active portions of a FRD3 protein can be used as targets for developing agents which modulate a FRD3 mediated activity, *e.g.*, modulation of metal concentrations.

In one embodiment, a biologically active portion of a FRD3 protein comprises at least one transmembrane domain. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native FRD3 protein.

In a preferred embodiment, the FRD3 protein has an amino acid sequence shown in SEQ ID NO:3, 6, 9, or 10. In other embodiments, the FRD3 protein is substantially identical to SEQ ID NO:3, 6, 9, or 10 and retains the functional activity of

the protein of SEQ ID NO:3, 6, 9, or 10 yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail in subsection I above.

Accordingly, in another embodiment, the FRD3 protein is a protein which comprises an amino acid sequence at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%,
5 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO: 3, 6, 9, or 10.

To determine the percent identity of two amino acid sequences or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-identical sequences can be disregarded for
10 comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, and even more preferably at least 70%, 80%, or 90% of the length of the reference sequence (*e.g.*, when aligning a second sequence to the FRD3 amino acid sequence of SEQ ID NO:2 having 526 amino
15 acid residues, at least 158, preferably at least 210, more preferably at least 263, even more preferably at least 316, even more preferably at least 368, and even more preferably at least 421 or more amino acid residues are aligned). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino
20 acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which
25 need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (*J. Mol. Biol.* (48):444-453 (1970))
30 algorithm which has been incorporated into the GAP program in the GCG software package (available at the GCG website), using either a Blosum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package
35 (available at the GCG website), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment,

the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Meyers and W. Miller (*Comput. Appl. Biosci.*, 4: 11-17 (1988)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

5 The nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, *et al.* (1990) *J. Mol. Biol.* 215:403-10. BLAST nucleotide searches can be performed with the
10 NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to *frd3* nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 100, wordlength = 3 to obtain amino acid sequences homologous to FRD3 protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as
15 described in Altschul *et al.*, (1997) *Nucleic Acids Res.* 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (*e.g.*, XBLAST and NBLAST) can be used. See the NCBI website.

 The invention also provides FRD3 chimeric or fusion proteins. As used herein, a FRD3 "chimeric protein" or "fusion protein" comprises a FRD3 polypeptide
20 operatively linked to a non-FRD3 polypeptide. A "FRD3 polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a FRD3 molecule, whereas a "non-FRD3 polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially homologous to the FRD3 protein, *e.g.*, a protein which is different from the FRD3 protein and which is derived from the
25 same or a different organism. Within a FRD3 fusion protein the FRD3 polypeptide can correspond to all or a portion of a FRD3 protein. In a preferred embodiment, a FRD3 fusion protein comprises at least one biologically active portion of a FRD3 protein. In another preferred embodiment, a FRD3 fusion protein comprises at least two biologically active portions of a FRD3 protein. Within the fusion protein, the term
30 "operatively linked" is intended to indicate that the FRD3 polypeptide and the non-FRD3 polypeptide are fused in-frame to each other. The non-FRD3 polypeptide can be fused to the N-terminus or C-terminus of the FRD3 polypeptide.

 For example, in one embodiment, the fusion protein is a GST-FRD3 fusion protein in which the FRD3 sequences are fused to the C-terminus of the GST
35 sequences. Such fusion proteins can facilitate the purification of recombinant FRD3.

In another embodiment, the fusion protein is a FRD3 protein containing a heterologous signal sequence at its N-terminus. In certain host cells (*e.g.*, mammalian host cells), expression and/or secretion of FRD3 can be increased through use of a heterologous signal sequence.

5 The FRD3 fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject *in vivo*. The FRD3 fusion proteins can be used to affect the bioavailability of a FRD3 substrate. Use of FRD3 fusion proteins may be useful therapeutically for the treatment of disorders caused by, for example, (i) aberrant modification or mutation of a gene encoding a FRD3 protein;
10 (ii) mis-regulation of the *frd3* gene; and (iii) aberrant post-translational modification of a FRD3 protein.

 Moreover, the FRD3 fusion proteins of the invention can be used as immunogens to produce anti-FRD3 antibodies in a subject, to purify FRD3 ligands and in screening assays to identify molecules which inhibit the interaction of FRD3 with a
15 FRD3 substrate.

 Preferably, a FRD3 chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or
20 stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried
25 out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel *et al.* John Wiley & Sons: 2002). Moreover, many expression vectors are commercially available that already encode a fusion moiety (*e.g.*, a GST polypeptide). A *frd3*-encoding nucleic acid can be cloned into such an expression vector
30 such that the fusion moiety is linked in-frame to the FRD3 protein.

 The present invention also pertains to variants of the FRD3 proteins which function as either FRD3 agonists (mimetics) or as FRD3 antagonists. Variants of the FRD3 proteins can be generated by mutagenesis, *e.g.*, discrete point mutation or
35 truncation of a FRD3 protein. An agonist of the FRD3 proteins can retain substantially the same, or a subset, of the biological activities of the naturally occurring form of a

FRD3 protein. An antagonist of a FRD3 protein can inhibit one or more of the activities of the naturally occurring form of the FRD3 protein by, for example, competitively modulating a FRD3-mediated activity of a FRD3 protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one
5 embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the FRD3 protein.

In one embodiment, variants of a FRD3 protein which function as either FRD3 agonists (mimetics) or as FRD3 antagonists can be identified by screening
10 combinatorial libraries of mutants, *e.g.*, truncation mutants, of a FRD3 protein for FRD3 protein agonist or antagonist activity. In one embodiment, a variegated library of FRD3 variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of FRD3 variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides
15 into gene sequences such that a degenerate set of potential *frd3* sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (*e.g.*, for phage display) containing the set of *frd3* sequences therein. There are a variety of methods which can be used to produce libraries of potential FRD3 variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence
20 can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential FRD3 sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (see, *e.g.*, Narang, S.A. (1983) *Tetrahedron* 39:3; Itakura *et al.* (1984) *Annu. Rev.*
25 *Biochem.* 53:323; Itakura *et al.* (1984) *Science* 198:1056; Ike *et al.* (1983) *Nucleic Acid Res.* 11:477.

In addition, libraries of fragments of a FRD3 protein coding sequence can be used to generate a variegated population of FRD3 fragments for screening and subsequent selection of variants of a FRD3 protein. In one embodiment, a library of
30 coding sequence fragments can be generated by treating a double stranded PCR fragment of a *frd3* coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by
35 treatment with S1 nuclease, and ligating the resulting fragment library into an expression

vector. By this method, an expression library can be derived which encodes N-terminal, C-terminal and internal fragments of various sizes of FRD3 protein.

Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA
5 libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of FRD3 proteins. The most widely used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting
10 library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify FRD3 variants (Arkin and Yourvan (1992) *Proc.*
15 *Natl. Acad. Sci. USA* 89:7811-7815; Delgrave *et al.* (1993) *Protein Engineering* 6(3): 327-331).

In one embodiment, cell based assays can be exploited to analyze a variegated FRD3 library. For example, a library of expression vectors can be transfected into a cell line which ordinarily responds to a FRD3 ligand in a particular FRD3 ligand-
20 dependent manner. The transfected cells are then contacted with a FRD3 ligand and the effect of expression of the mutant on, *e.g.*, modulation of iron concentrations can be detected. Plasmid DNA can then be recovered from the cells which score for inhibition, or alternatively, potentiation of signaling by the FRD3 ligand, and the individual clones further characterized.

25 An isolated FRD3 protein, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind FRD3 using standard techniques for polyclonal and monoclonal antibody preparation. A full-length FRD3 protein can be used or, alternatively, the invention provides antigenic peptide fragments of FRD3 for use as immunogens. The antigenic peptide of FRD3 comprises at least 8 amino acid
30 residues of the amino acid sequence shown in SEQ ID NO:3, 6, 9, or 10 and encompasses an epitope of FRD3 such that an antibody raised against the peptide forms a specific immune complex with the FRD3 protein. Preferably, the antigenic peptide comprises at least 10 amino acid residues, more preferably at least 15 amino acid residues, even more preferably at least 20 amino acid residues, and most preferably at
35 least 30 amino acid residues.

Preferred epitopes encompassed by the antigenic peptide are regions of FRD3 that are located on the surface of the protein, *e.g.*, hydrophilic regions, as well as regions with high antigenicity.

5 A FRD3 immunogen typically is used to prepare antibodies by immunizing a suitable subject, (*e.g.*, rabbit, goat, mouse or other mammal) with the immunogen. An appropriate immunogenic preparation can contain, for example, recombinantly expressed FRD3 protein or a chemically synthesized FRD3 polypeptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory agent. Immunization of a suitable
10 subject with an immunogenic FRD3 preparation induces a polyclonal anti-FRD3 antibody response.

Accordingly, another aspect of the invention pertains to anti-FRD3 antibodies. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, *i.e.*, molecules that
15 contain an antigen binding site which specifically binds (immunoreacts with) an antigen, such as FRD3. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab')₂ fragments which can be generated by treating the antibody with an enzyme such as pepsin. The invention provides polyclonal and monoclonal antibodies that bind FRD3 molecules. The term "monoclonal antibody" or
20 "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of FRD3. A monoclonal antibody composition thus typically displays a single binding affinity for a particular FRD3 protein with which it immunoreacts.

25 Polyclonal anti-FRD3 antibodies can be prepared as described above by immunizing a suitable subject with a FRD3 immunogen. The anti-FRD3 antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized FRD3. If desired, the antibody molecules directed against FRD3 can be isolated from the mammal
30 (*e.g.*, from the blood) and further purified by well known techniques, such as protein A chromatography to obtain the IgG fraction. At an appropriate time after immunization, *e.g.*, when the anti-FRD3 antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein
35 (1975) *Nature* 256:495-497) (see also, Brown *et al.* (1981) *J. Immunol.* 127:539-46; Brown *et al.* (1980) *J. Biol. Chem.* 255:4980-83; Yeh *et al.* (1976) *Proc. Natl. Acad.*

5 *Sci. USA* 76:2927-31; and Yeh *et al.* (1982) *Int. J. Cancer* 29:269-75), the more recent human B cell hybridoma technique (Kozbor *et al.* (1983) *Immunol Today* 4:72), the EBV-hybridoma technique (Cole *et al.* (1985), *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96) or trioma techniques. The technology for
10 producing monoclonal antibody hybridomas is well known (see generally R. H. Kenneth, in *Monoclonal Antibodies: A New Dimension In Biological Analyses*, Plenum Publishing Corp., New York, New York (1980); E. A. Lerner (1981) *Yale J. Biol. Med.*, 54:387-402; M. L. Gefter *et al.* (1977) *Somatic Cell Genet.* 3:231-36). Briefly, an
15 immortal cell line (typically a myeloma) is fused to lymphocytes (typically splenocytes) from a mammal immunized with a FRD3 immunogen as described above, and the culture supernatants of the resulting hybridoma cells are screened to identify a
20 hybridoma producing a monoclonal antibody that binds FRD3.

Any of the many well known protocols used for fusing lymphocytes and immortalized cell lines can be applied for the purpose of generating an anti-FRD3
25 monoclonal antibody (see, *e.g.*, G. Galfre *et al.* (1977) *Nature* 266:55052; Gefter *et al. Somatic Cell Genet.*, cited *supra*; Lerner, *Yale J. Biol. Med.*, cited *supra*; Kenneth, *Monoclonal Antibodies*, cited *supra*). Moreover, the ordinarily skilled worker will appreciate that there are many variations of such methods which also would be useful. Typically, the immortal cell line (*e.g.*, a myeloma cell line) is derived from the same
30 mammalian species as the lymphocytes. For example, murine hybridomas can be made by fusing lymphocytes from a mouse immunized with an immunogenic preparation of the present invention with an immortalized mouse cell line. Preferred immortal cell lines are mouse myeloma cell lines that are sensitive to culture medium containing hypoxanthine, aminopterin and thymidine ("HAT medium"). Any of a number of
35 myeloma cell lines can be used as a fusion partner according to standard techniques, *e.g.*, the P3-NS1/1-Ag4-1, P3-x63-Ag8.653 or Sp2/O-Ag14 myeloma lines. These myeloma lines are available from ATCC. Typically, HAT-sensitive mouse myeloma cells are fused to mouse splenocytes using polyethylene glycol ("PEG"). Hybridoma cells resulting from the fusion are then selected using HAT medium, which kills unfused and
unproductively fused myeloma cells (unfused splenocytes die after several days because they are not transformed). Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind FRD3, *e.g.*, using a standard ELISA assay.

Alternative to preparing monoclonal antibody-secreting hybridomas, a
35 monoclonal anti-FRD3 antibody can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (*e.g.*, an antibody phage display

library) with FRD3 to thereby isolate immunoglobulin library members that bind FRD3. Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia *Recombinant Phage Antibody System*, Catalog No. 27-9400-01; and the Stratagene *SurfZAP™ Phage Display Kit*, Catalog No. 240612). Additionally,

5 examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, Ladner *et al.* U.S. Patent No. 5,223,409; Kang *et al.* PCT International Publication No. WO 92/18619; Dower *et al.* PCT International Publication No. WO 91/17271; Winter *et al.* PCT International Publication WO 92/20791; Markland *et al.* PCT International Publication No. WO

10 92/15679; Breitling *et al.* PCT International Publication WO 93/01288; McCafferty *et al.* PCT International Publication No. WO 92/01047; Garrard *et al.* PCT International Publication No. WO 92/09690; Ladner *et al.* PCT International Publication No. WO 90/02809; Fuchs *et al.* (1991) *Bio/Technology* 9:1370-1372; Hay *et al.* (1992) *Hum. Antibod. Hybridomas* 3:81-85; Huse *et al.* (1989) *Science* 246:1275-1281; Griffiths *et al.*

15 (1993) *EMBO J* 12:725-734; Hawkins *et al.* (1992) *J. Mol. Biol.* 226:889-896; Clarkson *et al.* (1991) *Nature* 352:624-628; Gram *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:3576-3580; Garrad *et al.* (1991) *Bio/Technology* 9:1373-1377; Hoogenboom *et al.* (1991) *Nuc. Acid Res.* 19:4133-4137; Barbas *et al.* (1991) *Proc. Natl. Acad. Sci. USA* 88:7978-7982; and McCafferty *et al.* *Nature* (1990) 348:552-554.

20 Additionally, recombinant anti-FRD3 antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in

25 Robinson *et al.* International Application No. PCT/US86/02269; Akira, *et al.* European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison *et al.* European Patent Application 173,494; Neuberger *et al.* PCT International Publication No. WO 86/01533; Cabilly *et al.* U.S. Patent No. 4,816,567; Cabilly *et al.* European Patent Application 125,023; Better *et al.* (1988) *Science*

30 240:1041-1043; Liu *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:3439-3443; Liu *et al.* (1987) *J. Immunol.* 139:3521-3526; Sun *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:214-218; Nishimura *et al.* (1987) *Canc. Res.* 47:999-1005; Wood *et al.* (1985) *Nature* 314:446-449; and Shaw *et al.* (1988) *J. Natl. Cancer Inst.* 80:1553-1559; Morrison, S. L. (1985) *Science* 229:1202-1207; Oi *et al.* (1986) *BioTechniques* 4:214;

35 Winter U.S. Patent 5,225,539; Jones *et al.* (1986) *Nature* 321:552-525; Verhoeyan *et al.* (1988) *Science* 239:1534; and Beidler *et al.* (1988) *J. Immunol.* 141:4053-4060.

An anti-FRD3 antibody (*e.g.*, monoclonal antibody) can be used to isolate FRD3 by standard techniques, such as affinity chromatography or immunoprecipitation. An anti-FRD3 antibody can facilitate the purification of natural FRD3 from cells and of recombinantly produced FRD3 expressed in host cells. Moreover, an anti-FRD3

5 antibody can be used to detect FRD3 protein (*e.g.*, in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the FRD3 protein. Anti-FRD3 antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, *e.g.*, to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (*i.e.*, physically linking) the

10 antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin;

15 examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

20

III. Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a FRD3 protein (or a portion thereof). As used herein, the term “vector” refers to a nucleic acid molecule capable of transporting

25 another nucleic acid to which it has been linked. One type of vector is a “plasmid”, which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial

30 vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as “expression

35 vectors”. In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, “plasmid” and “vector” can

be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (*e.g.*, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

5 The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant
10 expression vector, “operably linked” is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (*e.g.*, in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term “regulatory
15 sequence” is intended to include promoters, enhancers and other expression control elements (*e.g.*, polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cells and those which direct expression of the nucleotide sequence only in certain host cells (*e.g.*,
20 tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, and the like. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as
25 described herein (*e.g.*, FRD3 proteins, mutant forms of FRD3 proteins, fusion proteins, and the like).

 The recombinant expression vectors of the invention can be designed for expression of FRD3 proteins in prokaryotic or eukaryotic cells. For example, FRD3 proteins can be expressed in bacterial cells such as *E. coli*, insect cells (using
30 baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

35 Expression of proteins in prokaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of

either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith, D.B. and Johnson, K.S. (1988) *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Purified fusion proteins can be utilized in FRD3 activity assays, (*e.g.*, direct assays or competitive assays described in detail below), or to generate antibodies specific for FRD3 proteins, for example. In a preferred embodiment, a FRD3 fusion protein expressed in a retroviral expression vector of the present invention can be utilized to infect bone marrow cells which are subsequently transplanted into irradiated recipients. The pathology of the subject recipient is then examined after sufficient time has passed (*e.g.*, six (6) weeks).

Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann *et al.*, (1988) *Gene* 69:301-315) and pET 11d (Studier *et al.*, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 60-89). Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET 11d vector relies on transcription from a T7 gn10-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident prophage harboring a T7 gn1 gene under the transcriptional control of the lacUV 5 promoter.

One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an

expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (Wada *et al.*, (1992) *Nucleic Acids Res.* 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

5 In another embodiment, the FRD3 expression vector is a yeast expression vector. Examples of vectors for expression in yeast *S. cerevisiae* include pYepSec1 (Baldari, *et al.*, (1987) *Embo J.* 6:229-234), pMFa (Kurjan and Herskowitz, (1982) *Cell* 30:933-943), pJRY88 (Schultz *et al.*, (1987) *Gene* 54:113-123), pYES2 (Invitrogen Corporation, San Diego, CA), and picZ (Invitrogen Corp, San Diego, CA).

10 Alternatively, FRD3 proteins can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (*e.g.*, Sf 9 cells) include the pAc series (Smith *et al.* (1983) *Mol. Cell Biol.* 3:2156-2165) and the pVL series (Lucklow and Summers (1989) *Virology* 170:31-39).

15 In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, B. (1987) *Nature* 329:840) and pMT2PC (Kaufman *et al.* (1987) *EMBO J.* 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements.

20 For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY,*
25 1989.

 In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (*e.g.*, tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable
30 tissue-specific promoters include the albumin promoter (liver-specific; Pinkert *et al.* (1987) *Genes Dev.* 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) *Adv. Immunol.* 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) *EMBO J.* 8:729-733) and immunoglobulins (Banerji *et al.* (1983) *Cell* 33:729-740; Queen and Baltimore (1983) *Cell* 33:741-748), neuron-specific promoters
35 (*e.g.*, the neurofilament promoter; Byrne and Ruddle (1989) *Proc. Natl. Acad. Sci. USA* 86:5473-5477), pancreas-specific promoters (Edlund *et al.* (1985) *Science* 230:912-916),

lung specific promoters, and mammary gland-specific promoters (*e.g.*, milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990) *Science* 249:374-379) and the α -fetoprotein promoter (Campes and Tilghman (1989) *Genes Dev.* 3:537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to *frd3* mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub, H. *et al.*, Antisense RNA as a molecular tool for genetic analysis, *Reviews - Trends in Genetics*, Vol. 1(1) 1986.

Another aspect of the invention pertains to host cells into which a *frd3* nucleic acid molecule of the invention is introduced, *e.g.*, a *frd3* nucleic acid molecule within a recombinant expression vector or a *frd3* nucleic acid molecule containing sequences which allow it to homologously recombine into a specific site of the host cell's genome. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, a FRD3 protein can be expressed in bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

5 Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (*e.g.*, DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated
10 transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, *et al.* (*Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), and other laboratory manuals.

 For stable transfection of mammalian cells, it is known that, depending
15 upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (*e.g.*, resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418,
20 hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding a FRD3 protein or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (*e.g.*, cells that have incorporated the selectable marker gene will survive, while the other cells die).

25 A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (*i.e.*, express) a FRD3 protein. Accordingly, the invention further provides methods for producing a FRD3 protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of the invention (into which a recombinant expression vector encoding a FRD3 protein has
30 been introduced) in a suitable medium such that a FRD3 protein is produced. In another embodiment, the method further comprises isolating a FRD3 protein from the medium or the host cell.

 The host cells of the invention can also be used to produce transgenic plants. As used herein, the term "transgenic" refers to a cell, group of cells, or organism,
35 *e.g.*, plant or animal, which includes a DNA sequence which is inserted by artifice therein. If the DNA sequence is inserted into a cell, the sequence becomes part of the

genome of the organism which develops from that cell. For example, the transgenic organisms are generally transgenic plants and the DNA transgene is inserted artificially into the nuclear or plastidic genome. As used herein, the term "transgene" refers to any piece of DNA which is artificially inserted into a cell, group of cells, or organism, *e.g.*,
5 plant or animal, and becomes a part of the genome of the organism which develops from that cell. Such a transgene can include a gene which is partly or entirely heterologous to the transgenic organism, or can include a gene homologous to an endogenous gene of the organism.

For example, in one embodiment, a host cell of the invention is a plant
10 cell, *e.g.*, a protoplast, into which *frd3*-coding sequences have been introduced. As used herein, a "plant cell" refers to any self-propagating cell bounded by a semi-permeable membrane and containing a plastid. Such a cell requires a cell wall if further propagation is desired. For example, plant cells of the invention include algae, cyanobacteria, seed suspension cultures, embryos, meristematic regions, callus tissue,
15 leaves, roots, shoots, gametophytes, sporophytes, pollen, and microspores. As used herein, the term "plant" refers to either a whole plant, a plant part, a plant cell, or a group of plant cells. The class of plants which can be used in the method of the invention is generally as broad as the class of higher plants amenable to transformation techniques, including both monocotyledonous and dicotyledonous plants. It includes plants of a
20 variety of ploidy levels, including polyploid, diploid and haploid.

The transformation of plants in accordance with the invention can be carried out in essentially any of the various ways known to those skilled in the art of plant molecular biology. See, in general, *Methods in Enzymology* Vol. 153 ("Recombinant DNA Part D") 1987, Wu and Grossman Eds., Academic Press and
25 European Patent Application EP 693554.

Selection of an appropriate vector is relatively simple, as the constraints are minimal. The minimal traits of the vector are that the desired nucleic acid sequence be introduced in a relatively intact state. Thus any vector which produces a plant carrying the introduced DNA sequence is sufficient. Also, any vector which introduces
30 a substantially intact RNA which can ultimately be converted into a stably maintained DNA sequence can be used to transform a plant cell.

Even a naked piece of DNA confers the properties of this invention, though at low efficiency. The decision as to whether to use a vector, or which vector to use, is determined by the method of transformation selected.

If naked nucleic acid introduction methods are chosen, then the vector need be no more than the minimal nucleic acid sequences necessary to confer the desired traits, without the need for additional other sequences. Thus, the possible vectors include the Ti plasmid vectors, shuttle vectors designed merely to maximally yield high numbers of copies, episomal vectors containing minimal sequences necessary for ultimate replication once transformation has occurred, transposon vectors, homologous recombination vectors, mini-chromosome vectors, and viral vectors, including the possibility of RNA forms of the gene sequences. The selection of vectors and methods to construct them are commonly known to persons of ordinary skill in the art and are described in general technical references (*Methods in Enzymology* Vol. 153 ("Recombinant DNA Part D") 1987, Wu and Grossman Eds., Academic Press).

In one embodiment, the foreign nucleic acid is mechanically transferred by microinjection directly into plant cells by use of micropipettes. Alternatively, the foreign nucleic acid can be transferred into the plant cell by using polyethylene glycol. This forms a precipitation complex with the genetic material that is taken up by the cell (Paszkowski *et al.* (1984) *EMBO J.* 3:2712-22).

In another embodiment, foreign nucleic acid can be introduced into the plant cells by electroporation (Fromm *et al.* (1985) *Proc. Natl. Acad. Sci. USA* 82:5824). In this technique, plant protoplasts are electroporated in the presence of plasmids or nucleic acids containing the relevant genetic construct. Electrical impulses of high field strength reversibly permeabilize biomembranes allowing the introduction of the plasmids. Electroporated plant protoplasts reform the cell wall, divide, and form a plant callus. Selection of the transformed plant cells with the transformed gene can be accomplished using phenotypic markers.

Cauliflower mosaic virus (CaMV) can also be used as a vector for introducing the foreign nucleic acid into plant cells (Hohn *et al.* (1982) "Molecular Biology of Plant Tumors," Academic Press, New York, pp. 549-560; Howell, U.S. Pat. No. 4,407,956). CaMV viral DNA genome is inserted into a parent bacterial plasmid creating a recombinant DNA molecule which can be propagated in bacteria. After cloning, the recombinant plasmid again can be cloned and further modified by introduction of the desired DNA sequence into the unique restriction site of the linker. The modified viral portion of the recombinant plasmid is then excised from the parent bacterial plasmid, and used to inoculate the plant cells or plants.

Another method of introduction of foreign nucleic acid into plant cells is high velocity ballistic penetration by small particles with the nucleic acid either within the matrix of small beads or particles, or on the surface (Klein *et al.* (1987) *Nature*

327:70-73). Although typically only a single introduction of a new nucleic acid segment is required, this method particularly provides for multiple introductions.

A preferred method of introducing the nucleic acids into plant cells is to infect a plant cell, an explant, a meristem or a seed with *Agrobacterium tumefaciens* transformed with the nucleic acid. Under appropriate conditions known in the art, the transformed plant cells are grown to form shoots, roots, and develop further into plants. The nucleic acids can be introduced into appropriate plant cells, for example, by means of the Ti plasmid of *Agrobacterium tumefaciens*. The Ti plasmid is transmitted to plant cells upon infection by *Agrobacterium tumefaciens*, and is stably integrated into the plant genome (Horsch *et al.* (1984) "Inheritance of Functional Foreign Genes in Plants," *Science* 233:496-498; Fraley *et al.* (1983) *Proc. Natl. Acad. Sci. USA* 80:4803).

Ti plasmids contain two regions essential for the production of transformed cells. One of these, named transfer DNA (T DNA), induces tumor formation. The other, termed virulent region, is essential for the introduction of the T DNA into plants. The transfer DNA region, which transfers to the plant genome, can be increased in size by the insertion of the foreign nucleic acid sequence without affecting its transferring ability. By removing the tumor-causing genes so that they no longer interfere, the modified Ti plasmid can then be used as a vector for the transfer of the gene constructs of the invention into an appropriate plant cell.

There are presently at least three different ways to transform plant cells with *Agrobacterium*: (1) co-cultivation of *Agrobacterium* with cultured isolated protoplasts; (2) transformation of cells or tissues with *Agrobacterium*; or (3) transformation of seeds, apices or meristems with *Agrobacterium*. The first method requires an established culture system that allows culturing protoplasts and plant regeneration from cultured protoplasts. The second method requires that the plant cells or tissues can be transformed by *Agrobacterium* and that the transformed cells or tissues can be induced to regenerate into whole plants. The third method requires micropropagation.

In the binary system, to have infection, two plasmids are needed: a T-DNA containing plasmid and a vir plasmid. Any one of a number of T-DNA containing plasmids can be used, the only requirement is that one be able to select independently for each of the two plasmids.

After transformation of the plant cell or plant, those plant cells or plants transformed by the Ti plasmid so that the desired DNA segment is integrated can be selected by an appropriate phenotypic marker. These phenotypic markers include, but

are not limited to, antibiotic resistance, herbicide resistance or visual observation. Other phenotypic markers are known in the art and can be used in this invention.

All plants from which protoplasts can be isolated and cultured to give whole regenerated plants can be transformed by the present invention so that whole plants are recovered which contain the transferred foreign gene. Some suitable plants include, for example, species from the genera *Fragaria*, *Lotus*, *Medicago*, *Onobrychis*, *Trifolium*, *Trigonella*, *Vigna*, *Citrus*, *Linum*, *Geranium*, *Manihot*, *Daucus*, *Arabidopsis*, *Brassica*, *Raphanus*, *Sinapis*, *Atropa*, *Capsicum*, *Hyoscyamus*, *Lycopersicon*, *Nicotiana*, *Solanum*, *Petunia*, *Digitalis*, *Majorana*, *Cichorium*, *Helianthus*, *Lactuca*, *Bromus*, *Asparagus*, *Antirrhinum*, *Hererocallis*, *Nemesia*, *Pelargonium*, *Panicum*, *Pennisetum*, *Ranunculus*, *Senecio*, *Salpiglossis*, *Cucumis*, *Browaalia*, *Glycine*, *Lolium*, *Zea*, *Triticum*, *Sorghum*, and *Datura*.

Practically all plants can be regenerated from cultured cells or tissues. The term "regeneration" as used herein, means growing a whole plant from a plant cell, a group of plant cells, a plant part or a plant piece (e.g. from a protoplast, callus, or tissue part) (*Methods in Enzymology* Vol. 153 ("Recombinant DNA Part D") 1987, Wu and Grossman Eds., Academic Press; also *Methods in Enzymology*, Vol. 118; and Klee *et al.*, (1987) *Annual Review of Plant Physiology*, 38:467-486).

Plant regeneration from cultural protoplasts is described in Evans *et al.*, "Protoplasts Isolation and Culture," *Handbook of Plant Cell Cultures* 1:124-176 (MacMillan Publishing Co. New York 1983); M.R. Davey, "Recent Developments in the Culture and Regeneration of Plant Protoplasts," *Protoplasts* (1983)-Lecture Proceedings, pp. 12-29, (Birkhauser, Basel 1983); P.J. Dale, "Protoplast Culture and Plant Regeneration of Cereals and Other Recalcitrant Crops," *Protoplasts* (1983)-Lecture Proceedings, pp. 31-41, (Birkhauser, Basel 1983); and H. Binding, "Regeneration of Plants," *Plant Protoplasts*, pp. 21-73, (CRC Press, Boca Raton 1985).

Regeneration from protoplasts varies from species to species of plants, but generally a suspension of transformed protoplasts containing copies of the exogenous sequence is first generated. In certain species, embryo formation can then be induced from the protoplast suspension, to the stage of ripening and germination as natural embryos. The culture media can contain various amino acids and hormones, such as auxin and cytokinins. It can also be advantageous to add glutamic acid and proline to the medium, especially for such species as corn and alfalfa. Shoots and roots normally develop simultaneously. Efficient regeneration will depend on the medium, on the genotype, and on the history of the culture. If these three variables are controlled, then regeneration is fully reproducible and repeatable.

In vegetatively propagated crops, the mature transgenic plants are propagated by the taking of cuttings or by tissue culture techniques to produce multiple identical plants for trialling, such as testing for production characteristics. Selection of a desirable transgenic plant is made and new varieties are obtained thereby, and
5 propagated vegetatively for commercial sale. In seed propagated crops, the mature transgenic plants are self crossed to produce a homozygous inbred plant. The inbred plant produces seed containing the gene for the newly introduced foreign gene activity level. These seeds can be grown to produce plants that have the selected phenotype. The inbreds according to this invention can be used to develop new hybrids. In this
10 method a selected inbred line is crossed with another inbred line to produce the hybrid.

Parts obtained from the regenerated plant, such as flowers, seeds, leaves, branches, fruit, and the like are covered by the invention, provided that these parts comprise cells which have been so transformed. Progeny and variants, and mutants of the regenerated plants are also included within the scope of this invention, provided that
15 these parts comprise the introduced DNA sequences. Progeny and variants, and mutants of the regenerated plants are also included within the scope of this invention.

However, any additional attached vector sequences which confers resistance to degradation of the nucleic acid fragment to be introduced, which assists in the process of genomic integration or provides a means to easily select for those cells or
20 plants which are transformed are advantageous and greatly decrease the difficulty of selecting useable transgenic plants or plant cells.

Selection of transgenic plants or plant cells is typically be based upon a visual assay, such as observing color changes (*e.g.*, a white flower, variable pigment production, and uniform color pattern on flowers or irregular patterns), but can also
25 involve biochemical assays of either enzyme activity or product quantitation. Transgenic plants or plant cells are grown into plants bearing the plant part of interest and the gene activities are monitored, such as by visual appearance (for flavonoid genes) or biochemical assays (Northern blots); Western blots; enzyme assays and flavonoid compound assays, including spectroscopy, see, Harborne *et al.* (Eds.), (1975) *The*
30 *Flavonoids*, Vols. 1 and 2, [Acad. Press]). Appropriate plants are selected and further evaluated. Methods for generation of genetically engineered plants are further described in US Patent No. 5,283,184, US Patent No. 5, 482,852, and European Patent Application EP 693 554.

An example of a commercial application of the transgenic plants of the
35 invention is in agriculture. Iron is an essential nutrient for crop plants because it is required for the activity of iron-containing proteins involved in photosynthesis and

respiration. Although iron is abundant in the soil, its acquisition can be difficult under aerobic conditions because it is very insoluble at moderate pH. This issue is important in agriculture because a third of the world's soils are iron-deficient. Therefore, understanding how plants accumulate iron is critical for increased production of crops that would themselves be richer sources of iron in foods. The ability to develop transgenic plants, through manipulation of the *frd3* gene and other members of the MATE family, that are more efficient in extracting iron from soil has important agricultural implications.

A second example of a commercial application of the transgenic plants of the invention is in environmental pollution remediation. Removal of toxic metals from contaminated sites is particularly difficult. Unlike organic pollutants, metal pollutants cannot be biodegraded. The current method of removing metals from contaminated sites is excavation, removal of the soil, and burial in a hazardous waste site. Phytoremediation, the technique of using plants to extract metals from soil, is a more economical and environmentally-safe alternative. Genetically engineered plants of the present invention that are created to be metal specific present great potential for this technology. *IRT1* or other members of the MATE family can be manipulated in a plant species to allow high-level accumulation of a specific toxic metal from a contaminated soil.

IV. Pharmaceutical Compositions

The transgenic plant in which the expression of a FRD3 polypeptide is altered, or portions thereof, and other agents described herein can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the transgenic plant in which the expression of a FRD3 polypeptide is altered, a portion thereof, or agent and a pharmaceutically acceptable carrier. As used herein the term "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

In one embodiment, polypeptides, compositions, transgenic plants or portions thereof, of the invention can be administered to a subject to treat metal-deficiency, *e.g.*, iron- or zinc-deficiency, or can be administered to a subject, *e.g.*, human

or animal, as a nutritional supplement, *e.g.*, as a metal source, *e.g.*, as an iron or zinc supplement. The polypeptides, compositions, or plants are administered to the subjects in a biologically compatible form suitable for pharmaceutical administration *in vivo*. By "biologically compatible form suitable for administration *in vivo*" is meant a form of the polypeptide, composition, or plant, *e.g.*, transgenic plant, to be administered in which any toxic effects are outweighed by the therapeutic effects of the polypeptide composition or plant. Administration of a therapeutically active or therapeutically effective amount of a polypeptide, composition, or plant of the present invention is defined as an amount effective, at dosages and for periods of time necessary to achieve the desired result. For example, a therapeutically active amount of a transgenic plant in which expression of a FRD3 polypeptide is altered can vary according to factors such as the disease state, age, sex, and weight of the subject, and the ability of the composition to elicit a desired response in the subject. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, several divided doses can be administered daily or the dose can be proportionally reduced as indicated by the exigencies of the therapeutic situation.

The polypeptides, composition, or plant can be administered in a convenient manner such as by oral administration, *e.g.*, as a nutritional supplement, injection (subcutaneous, intravenous, etc.), and other methods of parenteral administration. Depending on the route of administration, the polypeptide, composition, or plant can be coated in a material to protect it from the action of enzymes, acids and other natural conditions which may inactivate the agent.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

In one embodiment, the polypeptides, compositions, or plants are prepared with carriers that protect them against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

To administer a polypeptide, composition, or plant by other than parenteral administration, it may be necessary to coat it with, or co-administer it with, a material to prevent its inactivation. For example, a transgenic plant in which expression of a FRD3 polypeptide is altered or a portion thereof can be administered to a subject in an appropriate carrier or diluent co-administered with enzyme inhibitors or in an appropriate carrier such as liposomes. Pharmaceutically acceptable diluents include saline and aqueous buffer solutions. Enzyme inhibitors include pancreatic trypsin inhibitor, diisopropylfluorophosphate (DEP) and trasylol. Liposomes include water-in-oil-in-water emulsions as well as conventional liposomes (Strejan *et al.* (1984) *J. Neuroimmunol* 7:27). Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations can contain a preservative to prevent the growth of microorganisms.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. In all cases, the

composition must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the polypeptide, composition, or plant in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the polypeptide, composition, or plant into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient (*e.g.*, peptide) plus any additional desired ingredient from a previously sterile-filtered solution thereof.

V. Uses and Methods of the Invention

The invention further pertains to methods for modulating metal concentration in a biological sample containing the metal or in a subject. These methods include providing a transgenic plant in which expression of a FRD3 polypeptide is altered and contacting the transgenic plant with the biological sample such that the metal concentration in the biological sample is modulated. The term "modulating" as used herein refers to increasing or decreasing the concentration of a metal in a biological sample. As used herein, the term "metal" includes stable metals and radioactive metals such as iron, lead, chromium, mercury, cadmium, cobalt, barium, nickel, molybdenum, copper, arsenic, selenium, zinc, antimony, beryllium, gold, manganese, silver, thallium,

tin, rubidium, vanadium, strontium, yttrium, technecium, ruthenium, palladium, indium, cesium, uranium, plutonium, and cerium. The term "metal" is also intended to include a mixture of two or more metals and mixtures of metals and common organic pollutants such as, for example, lead and chromium in combination with nitrophenol, benzene, and/or alkyl benzyl sulfonates (detergents). As used herein the phrase "biological sample" refers to a material, solid or liquid, in which it is desirable to modulate a metal concentration. Examples of biological samples include metal contaminated liquids such as industrial and residential waste streams, water-treatment plant effluents, ground and surface water, diluted sludge and other aqueous streams containing radioactive and nonradioactive metals, as well as soils or sediments. The soils or sediments can include a variety of soil types having wide ranges of water content, organic matter content, mineral content and metal content. As used herein, the phrase "transgenic plant in which expression of a FRD3 polypeptide is altered" refers to a transgenic plant in which a FRD3 polypeptide is misexpressed, *e.g.*, the expression of a FRD3 polypeptide is enhanced, induced, prevented or suppressed. For example, a transgenic plant in which a FRD3 polypeptide is altered, *e.g.*, by misexpression, can be a metal accumulating plant.

"Misexpression", as used herein, refers to a non-wild type pattern of gene expression. It includes: expression at non-wild type levels, *i.e.*, over or under expression; a pattern of expression that differs from wild type in terms of the time or stage at which the gene is expressed, *e.g.*, increased or decreased expression (as compared with wild type) at a predetermined developmental period or stage; a pattern of expression that differs from wild type in terms of decreased expression (as compared with wild type) in a predetermined cell type or tissue type; a pattern of expression that differs from wild type in terms of the splicing size, amino acid sequence, post-translational modification, or biological activity of the expressed polypeptide; a pattern of expression that differs from wild type in terms of the effect of an environmental stimulus or extracellular stimulus on expression of the gene, *e.g.*, a pattern of increased or decreased expression (as compared with wild type) in the presence of an increase or decrease in the strength of the stimulus.

To measure metal accumulation of a plant in a biological sample, seeds of a particular plant to be tested are grown in a greenhouse, the appropriate metal is administered to the plant and soil, and the roots and shoots harvested for routine determination of biomass and metal content. Chemical analysis of metal content in soils and plants is well characterized. See, *e.g.*, Blincoe *et al.* (1987) *Comm. Soil. Plant Anal.* 18: 687; Baker *et al.* (1982) "Atomic Absorption Spectrometry," pp. 13-17 in *Methods of Soil Analysis*, part 2, *Am. Soc. Agron.*, Madison, Wis.. Metal in plant tissues is

preferably assayed with plasma spectrometry, allowing ashing and acid extraction. Metal remaining in the solution is measured, for example, by atomic absorption or plasma spectrometry. See, *e.g.*, Soltanpour *et al.* (1982) "Optical emission spectrometry," pp. 29-65 in *Methods of Soil Analysis*, part 2, *Am. Soc. Agron.*, Madison, Wis.

Other methods of the invention include methods for removing a pollutant from soil, *e.g.*, phytoremediation (Guerinot, M.L. and Salt, D.E. (2001) *Plant Physiol.* 125: 164-167) These methods include contacting the transgenic plant in which expression of FRD3 polypeptide is altered with the soil such that the pollutant is removed from the soil, *i.e.*, the concentration of the pollutant in the soil prior to contact with the transgenic plant is greater than the concentration of the pollutant in the soil after contact with the transgenic plant. The term "pollutant" as used herein refers to any metal, *e.g.*, radioactive or nonradioactive metal, that is found in the soil at toxic levels. As used herein, the phrase "toxic levels" refers to the concentration of metal which is higher than the concentration at which these metals naturally occur in the soil. Such toxic levels are usually produced by industries and other pollution centers. For example, metals such as mercury, cobalt, lead, arsenic, cadmium, zinc, copper, alone or in combination with other metals and/or detergents, as described above, are known soil pollutants.

Still other methods of the present invention include methods for treating a disorder associated with metal-deficiency, *e.g.*, iron-deficiency or zinc-deficiency, in a subject. These methods include administering to a subject a therapeutically effective amount of a composition comprising the transgenic plant, or a portion thereof, in which expression of a FRD3 polypeptide is altered. In a preferred embodiment, the composition is administered in combination with a pharmaceutically acceptable carrier. In another preferred embodiment, the FRD3 polypeptide is overexpressed. Subjects who can be treated by the method of this invention include living organisms, *e.g.* mammals, *e.g.*, humans. Examples of preferred subjects are those who have or are susceptible to iron-deficiency or zinc-deficiency, *e.g.*, infants and women of childbearing age. As used herein, the phrase "a disorder associated with metal-deficiency" refers to any disease or disorder that results from a negative balance between metal intake and metal loss, *e.g.*, iron intake and iron loss or zinc intake and zinc loss. For example, whenever there is rapid growth, as occurs during infancy, early childhood, adolescence and pregnancy, positive iron balance is difficult to maintain. Iron-deficiency can be the result of low dietary iron content, especially bioavailable iron, while in areas endemic for hookworm, intestinal blood loss secondary to heavy infestation contributes to iron-deficiency in both

women and men. More severe forms of iron-deficiency usually result in anemia. In addition to iron, zinc is a metal with great nutritional importance, particularly during periods of rapid growth, due to its intervention in cellular replication as well as in development of the immune response. There is considerable evidence that zinc

5 deficiency in humans is a serious worldwide problem and outweighs the potential problem of accidental, self-imposed, or environmental exposure to zinc excess. Acute deficiency (Henkin *et al.* (1975) *Arch Neurol* 322:745-751) and chronic deficiency (Prasad A.S. (1991) *Am J Clin Nutr* 53:403-412) are well-known entities in human populations and are probably much more common than generally recognized. The

10 importance of zinc for human health was first documented in 1963 (Prasad *et al.* (1963) *J Lab Clin Med* 61:537-549). During the past 25 years, deficiency of zinc in humans due to nutritional factors and several disease states has now been documented throughout the world. Prevalence of zinc deficiency is high in populations that consume large quantities of cereal proteins containing high amounts of phytate, an organic

15 phosphate compound. Alcoholism, malabsorption, sickle cell anemia, chronic renal disease, and other chronically debilitating diseases are known to be predisposing factors for zinc deficiency in humans (Prasad AS, (Prasad, AS, ed.) (1988) *New York: Alan R. Liss* 3-53; Hambridge M. (2000) *J. Nutr.* 130: 1344S-1349S).

Based upon clinical data and using traditional, epidemiologic techniques,

20 Henkin and Aamodt (Henkin RI, Aamodt RL, (Inglett GE, ed.) (1983) *Washington: American Chemical Society* 83-105) have reclassified zinc deficiency into three syndromes; these are (a) acute, (b) chronic, and (c) subacute zinc deficiency. Acute zinc deficiency is relatively uncommon and follows parenteral hyperalimentation or oral L-histidine administration. Chronic zinc deficiency is more common, usually resulting

25 from chronic dietary lack of zinc. Subacute or latent zinc deficiency is the most common of these syndromes. It is estimated that there are 4 million people in the United States with this syndrome, the initial symptom being dysfunction of taste and olfaction; treatment with exogenous zinc restores taste and smell but this usually requires months before these functions are returned to normal (Henkin *et al.* (1976) *Am J Med Sci*

30 272:285-299). Diagnosis of these disorders is most efficacious following oral administration of zinc tracers such as ^{65}Zn , ^{67}Zn , or ^{70}Zn with subsequent evaluation of the kinetics of transfer of the isotope into various body tissues, the formulation of the data by compartmental analysis, and the integration of the data by a systematic model of zinc metabolism.

Clinical symptoms of human zinc-deficiency states exhibit a spectrum ranging from mild to severe and may even be fatal if unrecognized and not corrected (Prasad, AS (Prasad, AS, ed.) (1988) *New York: Alan R. Liss*, 3-53). The clinical manifestations of severely zinc deficient subjects include bullous pustular dermatitis, diarrhea, alopecia, mental disturbances, and intercurrent infections due to cell-mediated immune disorders. These severe signs are seen in patients with acrodermatitis enteropathica secondary to an inborn error of zinc absorption, patients receiving total parenteral nutrition without zinc, and patients receiving penicillamine therapy. Growth retardation, male hypogonadism, skin changes, poor appetite, mental lethargy, abnormal dark adaptation, and delayed wound healing are usual manifestations of moderate deficiency of zinc. Recent studies show that a mild or marginal deficiency of zinc in humans is characterized by neurosensory changes, oligospermia in males, decreased serum testosterone in males, hyperammonemia, decreased serum thymulin activity, decreased IL-2 production, decreased natural killer cell activity, alterations in T cell subpopulations (Prasad, AS (Prasad, AS, ed.) (1988) *New York: Alan R. Liss*, 3-53), impaired neuropsychological functions (Penland, J.G. (1976) *FASEB, J* 5:A938), and decreased ethanol clearance (Milne *et al.* (1991) *Am J Clin Nutr* 53:25).

It has also been shown that DNA damage from micronutrient deficiencies are a likely major cause of cancer (Ames, B. (2001) *Mutation Res.* 475: 7-20). Accordingly, compositions of the present invention are useful in treating and preventing cancer.

The compositions of the invention can be administered to the subject by a route of administration which allows the composition to perform its intended function. Various routes of administration are described herein in the section entitled "Pharmaceutical Compositions". Administration of a therapeutically active or therapeutically effective amount of the composition of the present invention is defined as an amount effective, at dosages and for periods of time, necessary to achieve the desired result.

Other aspects of the invention pertain to methods for evaluating a candidate compound for the ability to interact with, *e.g.*, bind, a FRD3 polypeptide. These methods include contacting the candidate compound with the FRD3 polypeptide and evaluating the ability of the candidate compound to interact with, *e.g.*, to bind or form a complex with the FRD3 polypeptide. These methods can be performed *in vitro*, *e.g.*, in a cell free system, or *in vivo*, *e.g.*, in a two-hybrid interaction trap assay. These methods can be used to identify naturally occurring molecules which interact with FRD3

polypeptides. They can also be used to find natural or synthetic inhibitors of FRD3 polypeptides.

Yet other aspects of the invention pertain to methods for identifying agents which modulate, *e.g.*, inhibit or activate/stimulate, a FRD3 polypeptide or expression thereof. Also contemplated by the invention are the agents which modulate, *e.g.*, inhibit or activate/stimulate FRD3 polypeptides or FRD3 polypeptide expression and which are identified according to methods of the present invention. In one embodiment, these methods include contacting a first polypeptide, *e.g.*, a naturally occurring ligand of FRD3, with a second polypeptide comprising a FRD3 polypeptide and an agent to be tested and determining binding of the second polypeptide to the first polypeptide. Inhibition of binding of the first polypeptide to the second polypeptide indicates that the agent is an inhibitor of a FRD3 polypeptide. Activation of binding of the first polypeptide to the second polypeptide indicates that the agent is an activator/stimulator of a FRD3 polypeptide.

This invention is further illustrated by the following examples which in no way should be construed as being further limiting. The contents of all cited references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated by reference.

EXAMPLES

Methods and Materials

Arabidopsis lines and growth conditions: The *Arabidopsis* (*Arabidopsis thaliana*) mutants *frd3-1*, *frd3-2* and the corresponding Columbia *gl-1* wild type have been described previously (Yi (1995) *Iron uptake in Arabidopsis thaliana*, Ph.D., Dartmouth College, Hanover, NH). *man1* was obtained from the *Arabidopsis* Biological Resource Center (<http://www.biosci.ohio-state.edu/~plantbio/Facilities/abrc/abrhome.htm>). Unless otherwise specified, plants were grown under sterile conditions as described previously (Yi and Guerinot (1996) Plant J. 10:835-844). Briefly, seeds were sown on Petri plates containing Gamborg's B5 media (Sigma) and grown until the 4 to 6 true leaf stage and then transferred to plates with or without 50 μ M Fe(III) EDTA for iron-sufficient or deficient conditions, respectively, for three days prior to analysis. Both Fe(III) chelate reductase assays and the pH plates were also described previously (Yi and Guerinot (1996)).

RNA blot hybridization: RNA isolation, RNA blotting and all molecular biology procedures were performed using standard protocols (Ausubel *et al.* (2001) Current Protocols in Molecular Biology. (New York, NY: John Wiley & Sons)). RNA blots (5 µg total RNA per lane) were visualized either by exposure to film for one to two days or to a Molecular Dynamics Typhoon PhosphoImager screen for 4 to 24 hours. *FRO2* and *IRT1* probes were made from previously published cDNA clones (Eide *et al.* (1996) Natl. Acad. Sci. USA 93:5624-5628; Robinson *et al.* (1999) Nature 397:694-697) and a *UBQ5* PCR product was amplified as described (Rogers and Ausubel (1997) Plant Cell 9:305-316). Probe DNA containing approximately 30 µC ³²P was used for each blot.

Immunoblots: Immunoblots were performed as previously described (Connolly *et al.* (2002) Plant Cell in press). Total protein was prepared from the roots and shoots of plants grown axenically on plates that were either iron-deficient or iron-sufficient. Extracts were prepared by grinding tissue (2 ml buffer per 1 g wet tissue) on ice in extraction buffer (50 mM Tris pH 8.0, 5% glycerol, 4% SDS, 1% polyvinylpyrrolidone, 1 mM PMSF), followed by centrifugation at 4°C for fifteen minutes at 14,000xg. The supernatant was recovered and total protein was estimated using the BCA protein assay (Pierce, Rockford, IL). Samples for SDS-PAGE were diluted with an equal volume of 2x sample prep buffer (Ausubel *et al.* (2001) Current Protocols in Molecular Biology. (New York, NY: John Wiley & Sons)) and boiled for two minutes. Total protein (10 µg) was separated by SDS-PAGE (Laemmli (1970) Nature 227:680-685) and transferred to polyvinylidene fluoride membrane by electroblotting (Towbin *et al.* (1979) Proc. Natl. Acad. Sci. USA 76:4350-4354). Membranes were blocked in 1xPBST (0.1% Tween 20 in 1xPBS) with 5% nonfat dry milk for 3 hr at 37°C and then washed 2 times in 1xPBST for 5 min each. The membranes were then incubated overnight at 4°C with an anti-IRT1 antibody (1:1,000 fold dilution in 1xPBST, 1% nonfat dry milk). The IRT1 antibody was raised and affinity purified against a synthetic peptide (PANDVTLPIKEDDSSN (SEQ ID NO:11)) that corresponds to amino acids 162 to 177 of the IRT1 deduced protein sequence and is unique to IRT1 (Quality Controlled Biochemicals, Inc.). Next, the membranes were washed in 1xPBST, 4 times for 15 min each. Membranes were then incubated for 1 hour with goat-anti-rabbit IgG conjugated to Horseradish peroxidase (HRP) (1:5000 dilution in 1xPBST, 1% nonfat dry milk) (Pierce) followed by 4 washes for 15 min each in 1xPBST. Chemiluminescence was performed using the Renaissance Western Blot Chemiluminescence Reagent according to the directions of the manufacturer (NEN Life Science Products).

Elemental Analysis: Approximately 200 plants grown under iron-sufficient or iron-deficient conditions were pooled and subjected to elemental analysis. Metal content of the tissue was determined by the Dartmouth Superfund Trace Metal
5 Core Facility by use of a magnetic sector-inductively coupled plasma-mass spectrometer (ICP-MS ELEMENT, Finnigan MAT) as previously described (Chen *et al.* (2000) Limnology and Oceanography 45:1525-1536.). All values obtained were within the linear sensitivity range for this instrument.

10 Detection of NA: Nicotianamine was extracted from Arabidopsis tissue as previously described (Pich *et al.* (2001) Planta 213:967-976). Briefly, samples were ground in liquid nitrogen, extracted in H₂O at 80°C, centrifuged and the supernatant was dried by lyophilization. Extracts were redissolved in H₂O and spotted on TLC plates,
15 which were developed in butanol:acetic acid: H₂O (4:1:1) (Shojima *et al.* (1989) Plant Cell Physiol. 30:673-677). NA was visualized after reaction with ninhydrin. Samples were co-chromatographed with chemically synthesized NA (the kind gift of Dr. Axel Pich, Oldenburg, Germany) for identification purposes.

frd3 Mapping and Complementation: CAPS, SSLP (simple sequence
20 length polymorphism), and RFLP (restriction fragment length polymorphism) markers, publicly available on the *Arabidopsis* Information Resource (TAIR) web page (<http://www.arabidopsis.org/home.html>), were used where possible to obtain a rough map position of *frd3*. AtMLP3, F6, and F7, are SSLP markers constructed around simple sequence repeats in the corresponding BAC sequence. F9 is an RFLP marker
25 identified experimentally. The polymorphism covered by F11 is from the Cereon *Arabidopsis* Polymorphism Collection (available on the TAIR web site) and was scored by sequencing PCR products of that region. The complementing clone was constructed by digesting BAC T8G24 and ligating the total digest into the binary vector pCambia2300 (<http://www.cambia.org.au/>) according to standard molecular biology
30 procedures (Ausubel *et al.* (2001)). The resulting clones were screened by PCR for the construct of interest. The complementing clone was introduced into the *frd3-1* mutant by *Agrobacterium*-mediated transformation (Clough and Bent (1998) Plant J. 16:735-743). 5'RACE was performed according to the instruction manual for the 5'RACE System for Rapid Amplification of cDNA Ends, Version 2.0 (Life Technologies).

DNA and Protein Sequence Analysis: DNA sequencing was performed at the Dartmouth Molecular Biology Core Facility on an ABI Prism 3100 Automated DNA Sequencer. Sequence was analyzed with the GCG (Genetics Computer Group) software package and by BLAST (<http://www.ncbi.nlm.nih.gov/BLAST/>). Multiple sequence alignments were performed using the BCM Search Launcher (<http://dot.imgen.bcm.tmc.edu:9331/multi-align/multi-align.html>). These alignments were transformed into dendograms using MEGA version 2.1 (<http://www.megasoftware.net/>) or colored using BoxShade (http://www.ch.embnet.org/software/BOX_form.html).

Example 1: Cloning of FRD3

An *Arabidopsis* mutant that constitutively expresses all three strategy I iron deficiency responses was identified. The *frd3* gene was mapped to a 55 kb interval on Chromosome III. The gene was identified by sequencing genomic DNA coding for candidate genes in this 55 kb interval from all three mutant alleles, *frd3-1*, *frd3-2*, and *man1* (renamed *frd3-3*). This sequence was compared to the publicly available genomic sequence. The identified open reading frame has different single base pair alterations in each of the three alleles. *frd3-1* has a C to A nucleotide change that yields an alanine to aspartic acid change in the protein. *frd3-2* has a single nucleotide deletion in the coding sequence which results in a frameshift and the addition of nine novel amino acids followed by a premature stop codon. *man1* has a G to A change at the first nucleotide of an intron. This leads to the retention of the intron in the cDNA and in the corresponding protein, this leads to the addition of two novel amino acids followed by a premature stop codon. A description of the MAN1 mutant is included in Delhaize, E. (1996) *Plant Physiol.* 111:849-855, the contents of which are herein incorporated by reference.

The accession number for the BAC, T8G24, containing this open reading frame is AC074395. As currently annotated, *frd3* is the second gene on this BAC. Its gene number is T8G24.8 and its protein ID is AAG50830.1. In the MIPS database, wild type FRD3 is At3g08040. There is one EST sequence for this gene, accession number AV546075. It consists of 376 base pairs from the 3' end of the cDNA. It was deposited by Kazusa and we obtained cDNA clone from them (clone number RZL08b02). The whole cDNA clone was sequenced, confirming the predicted splice sites and protein sequence. A RT-PCR product was also sequenced for *man1* around the site of the mutation in *man1*.

Example 2: Characterization of Wild Type FRD3 and Mutant FRD3

FRD3 proteins can be characterized with respect to their patterns of expression and localization. Based on previous RT-PCR experiments, FRD3 is expressed in *Arabidopsis* roots but not in shoots. FRD3 is present in the roots under both iron-sufficient and iron-deficient conditions. *In situ* hybridization techniques and a GUS translational fusion reporter gene construct can be used to determine when and where FRD3 is expressed, *e.g.*, in which particular cell types. Immunolocalization can be used to determine the subcellular location of FRD3, either with antibodies to an epitope-tagged version of FRD3 or with antibodies to FRD3 itself. FRD3 can also be overexpressed in a wild type *Arabidopsis* plant to determine if it confers phenotypes of interest.

It is also possible to characterize the biochemical function of FRD3. For example, FRD3 can be expressed in yeast (*Saccharomyces cerevisiae*) to test the FRD3 iron-binding or iron-transporting properties. FRD3 could bind or transport iron either alone or as iron complexed to a low molecular weight chelator, *e.g.*, nicotianamine, a non-protein amino acid and iron chelator that has been shown in other plants to be involved in iron homeostasis.

man1 is allelic to *frd3*: A comparison of wild type, *frd3-1*, *frd3-2*, and *man1* Fe(III) chelate reductase activities in both iron-sufficient and iron-deficient plants is shown in Figure 8A. In wild type (ecotype Columbia), Fe(III) chelate reductase activity is induced approximately 4-fold by iron deficiency. However, in all three of the mutants, Fe(III) chelate reductase activity is equivalent under iron-sufficient and iron-deficient growth conditions. In addition, cupric (Cu(II)) reductase activity is upregulated in the mutants (data not shown). The *Arabidopsis frd1* mutant lacks both Fe(III) chelate reductase activity and Cu(II) reductase activity (Yi and Guerinot (1996) Plant J. 10:835-844). Both reductase activities are restored by the addition of a wild-type *FRO2* gene (Robinson *et al.* (1999) Nature 397:694-697). Therefore, the Cu(II) reductase activity, as well as Fe(III) chelate reductase activity is attributed to the FRO2 protein.

Figure 8B shows Fe(III) chelate reductase activity of F1 progeny of the mutants crossed to the wild-type parent, and to each other. These plants were grown under iron-sufficient conditions to emphasize the mutant phenotype. F1 progeny from wild type crossed to each of the mutants show low, wild type levels of Fe(III) chelate reductase activity, demonstrating that all three of the mutations are recessive; in fact, all three segregate as single recessive Mendelian loci (data not shown). F1 progeny from mutant to mutant crosses all show high levels of reductase activity (Figure 8B)

comparable to the parental phenotype. This indicates that none of the three complement each other and are all alleles of the same locus. Therefore, *man1* has been renamed *frd3-3*.

5 In order to further investigate the Fe(III) chelate reductase activity, the expression of the *FRO2* Fe(III) chelate reductase gene was examined by RNA blot hybridization. Unlike the situation in wild type plants, *FRO2* is expressed constitutively in the roots of mutants carrying any *frd3*, i.e., any of the three alleles of *frd3* (data not shown). This is to be expected, because *FRO2* is the gene responsible for the iron deficiency induced root Fe(III) chelate reductase activity (Robinson *et al.* (1999), an activity that is constitutively present in *frd3*, the *frd3* mutant.

frd3 constitutively expresses all three Strategy I responses: To test if *frd3* constitutively expressed another Strategy I iron deficiency response, Fe(II) transport, the expression of the iron-regulated transporter *IRT1* was examined. The expression of *IRT1* parallels the expression of *FRO2*, with expression in the roots of *frd3* plants under both iron-sufficient and deficient conditions (data not shown). The IRT1 protein has been shown to be subject to post-transcriptional regulation (Connolly *et al.* (2002) Plant Cell in press) so it cannot be assumed that elevated mRNA levels correspond to elevated levels of IRT1 protein. Therefore, IRT1 protein levels were assayed by immunoblot (data not shown); the IRT1 protein does accumulate in iron-sufficient roots of the *frd3*. Therefore, *frd3* cannot sense iron levels and is responding in an iron-deficient manner under iron-sufficient growth conditions.

Because IRT1 was shown to transport iron, manganese and zinc when expressed in yeast (Eide *et al.* (1996) Natl. Acad. Sci. USA 93:5624-5628; Korshunova *et al.* (1999) Plant Mol. Biol. 40:37-44) and is overexpressed in *frd3*, shoot metal levels in the *frd3* were examined. As shown in Figure 9, mutants carrying all three alleles of the wild type *frd3* show 2-3x higher levels of iron, 2x higher levels of zinc and 3-4x higher levels of manganese in their shoots than the wild type. Copper levels were unchanged in the mutants (data not shown). *frd3-3* (*man1*) has previously been shown to have higher levels of zinc and manganese but not iron in its shoots (Delhaize (1996)). This difference might be accounted for by the different levels of iron in the media used in the two works. In this study, plants were grown on 100 μ M ferrous sulfate while in the work of Delhaize, 20 μ M Fe(III)EDDHA was used. In this study, iron levels of soil grown plants were similar in the wild type and *frd3* (data not shown), in agreement with results previously reported for soil grown *man1/frd3-3* plants (Delhaize (1996)). Recently, seeds produced by *man1* mutant plants were shown to have metal levels

similar to seeds from wild type plants (Lott and West (2001) Can. J. Bot. 79:1292-1296); this is in agreement with the results obtained here (data not shown).

It has been shown previously that levels of the iron chelator nicotianamine (NA) parallel iron levels in plant tissue (Pich *et al.* (2001) Planta 213:967-976). NA levels in the roots and the shoots of wild type and *frd3-1* mutant plants grown under both iron sufficient and iron-deficient conditions were examined by TLC. All samples from *frd3* plants contained at least 2-fold higher amounts of NA as compared to the corresponding sample from wild type plants (data not shown).

To show that *frd3* plants constitutively efflux protons, plants were grown with or without Fe(III) EDTA for three days and then transferred to bromocresol purple plates for 18 hr. Iron-deficient wild type (ecotype Columbia) and iron-sufficient and deficient *frd3-1* reduce the pH of the medium below 5.2 (data not shown). Iron-sufficient wild type causes the pH to rise above 7.0. Accordingly, based on pH indicator plates, *frd3-1* acidifies the media surrounding its roots when grown both under iron-sufficient and deficient conditions. In contrast, wild type only acidifies the surrounding media after being grown under iron-deficient conditions. Therefore, *frd3* plants constitutively efflux protons which is another Strategy I iron deficiency response. Thus, *frd3* plants constitutively express the three known Strategy I iron deficiency responses.

Cloning of wild type *frd3* by a map-based approach: To identify the molecular basis of the *frd3* phenotype, *frd3-1* was crossed to Landsberg-*erecta* (Ler) and mapped using CAPS (cleaved amplified polymorphic sequence) markers (Konieczny and Ausubel (1993) Plant J. 4:403-410). *frd3* mapped to the top of Chromosome 3, in agreement with published mapping data for *man1* (Delhaize (1996)). Approximately 820 homozygous mutant F2 progeny from the inter-ecotype cross were examined to refine the map position to a 55 kb interval as shown in Figure 10A. This interval was completely covered by a single BAC, F17A17 that was sequenced as part of the *Arabidopsis* Genome Initiative (AGI). Predicted open reading frames in this region were sequenced from one or more of the *frd3* alleles, looking for differences between the mutant and wild type sequences. Non-synonymous single base-pair alterations were found in all three alleles in one ORF in this region.

Expression of wild type genomic DNA containing only this ORF (marked by the striped box in Figure 10A) in *frd3-1* complements the chlorotic phenotype and restores the iron deficiency inducible Fe(III) chelate reductase activity (Figure 10B). Thereby identifying the gene containing the mutations responsible for the *frd3* phenotypes. Wild type *frd3* encodes an integral membrane protein 526 amino acids

long. The computer topology prediction program HMMTOP (Tusnady and Simon (2001) J. Mol. Biol. 283:489-506) predicts 12 transmembrane domains, as diagrammed in Figure 10C, with the N- and C-termini internal. Wild type FRD3 is predicted to localize to the plasma membrane according to PSORT (Nakai and Kanehisa (1992) Genomics 14:897-911) and TargetP (Emanuelsson *et al.* (2000) J. Mol. Biol. 300:1005-1016).

The wild type *frd3* gene corresponds to an EST sequence and the cDNA clone was obtained from the Kazusa DNA Research Institute and completely sequenced. The cDNA sequence has been deposited in Genbank (accession number AF448231). A string of As at the 3' end of the sequence and 5' RACE (rapid amplification of cDNA ends) confirmed that this clone was full length; the transcriptional start site is 117 bp upstream of the ATG. The cDNA sequence is consistent with the protein sequence predicted by AGI. Comparison of the wild type *frd3* genomic and cDNA sequences revealed that the wild type *frd3* gene has 13 exons and 12 introns, as diagrammed in Figure 10D. It is notable that the first intron is in the 5' untranslated region and is almost 2.6 kb in length; this is much larger than the approximately 170 bp average for *Arabidopsis* introns (*Arabidopsis* Genome Initiative (2000) Nature 408:796-815). Long introns in other *Arabidopsis* genes have been shown to play important roles in the regulation of gene expression (Jeon *et al.* (2000) Plant Physiol. 123:1005-1014).

Figure 10D also indicates the single nucleotide sequence changes in the three *frd3* mutant alleles. *frd3-1* has a C to A transversion. In the protein, this causes an aspartic acid to substitute for an alanine residue at position 54 in the first transmembrane domain (see Figure 10C). *frd3-2* has a deletion of a single G in the eighth exon, causing a frame shift and the addition of seven novel amino acids followed by a premature stop codon; *frd3-2* codes for approximately two-thirds of the wild type protein. *frd3-3* has a G to A transition in the first nucleotide of the fifth intron. Because this G is part of the required GT in a splice donor site, such a change would be predicted to lead to the retention of the intron. Sequence data from a *frd3-3* RT-PCR product confirms that this intron is retained (data not shown). This shifts the reading frame at a point approximately half way through the protein, leading to the addition of two novel amino acids followed by a premature stop codon.

frd3 Expression: The expression of wild type *frd3* and *frd3* in the roots is shown in Figure 11. No expression was detected in the shoots of wild type or any of the mutant alleles either by RNA blot hybridization or by RT-PCR (data not shown). In wild type, wild type *frd3* is expressed both under iron-sufficient and deficient conditions.

After normalization to the control gene *UBQ5*, wild type *frd3* mRNA levels are approximately 2-fold higher under iron deficiency. mRNA levels are considerably higher in plants carrying *frd3* than in wild type and higher when plants are grown under iron-sufficient conditions rather than iron-deficient conditions. The difference in wild type *frd3* mRNA levels under iron sufficiency varies from approximately 10-fold higher than wild type in *frd3-2* to almost 100-fold higher in *frd3-3*. Accordingly, wild type *frd3* is itself regulated by the process it controls. Because the wild type FRD3 is an integral membrane protein, this is an indirect effect.

10 Wild Type *frd3* and *frd3* are Members of the MATE Gene Family: Wild type FRD3 and FRD3 are members of the MATE (multi-drug and toxin efflux) family, an extensive group of membrane proteins involved in a variety of processes by functioning as a transporter of small organic molecules. In addition to *Arabidopsis*, there are MATE family members in humans, the yeasts *Saccharomyces cerevisiae* and 15 *Schizosaccharomyces pombe*, *Escherichia coli* and other bacteria, and archaea. *Arabidopsis* has 56 MATE family members, which is 10 times more than any other sequenced organism (*Arabidopsis* Genome Initiative (2000)). Figure 12 shows a dendogram which includes all 56 *Arabidopsis* proteins, one human protein, five proteins from yeast and selected bacterial members. The *Arabidopsis* genes fall into two main 20 groups. The top group in Figure 12 contains 50 *Arabidopsis* members and is loosely associated with the yeast and human family members. The other smaller group contains FRD3 and the bacterial NorM and DinF proteins.

Figure 13 shows an alignment of nine MATE proteins: five from *Arabidopsis*; the yeast protein ERC1; and three bacterial family members. These nine 25 proteins share sequence homology along their entire lengths except for the very N-terminal portion. As would be expected, the transmembrane domains are the most conserved. FRD3 is 57.8% identical to another *Arabidopsis* protein, FRD3-like or FRDL. FRD3 and FRDL are unique among the MATE family members shown in Figure 13 in possessing a larger cytoplasmic loop between transmembrane domains II 30 and III.

Equivalents Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the 35 invention described herein. Such equivalents are intended to be encompassed by the following claims.